Unnamed: 0 float64 0 700k | Date stringlengths 23 23 | Article_title stringlengths 1 250 | Stock_symbol stringlengths 1 5 | Url stringlengths 44 135 | Publisher float64 | Author float64 | Article stringlengths 1 343k ⌀ | Lsa_summary stringlengths 48 53.9k ⌀ | Luhn_summary stringlengths 1 53.9k ⌀ | Textrank_summary stringlengths 1 53.9k ⌀ | Lexrank_summary stringlengths 1 53.9k ⌀ |
|---|---|---|---|---|---|---|---|---|---|---|---|
23,500 | 2022-04-06 00:00:00 UTC | Warren Buffett's Top Stocks | ABBV | https://www.nasdaq.com/articles/warren-buffetts-top-stocks | null | null | Warren Buffett is often considered the greatest investor of all time. He has built Berkshire Hathaway (NYSE: BRK.B) into a multinational conglomerate holding company with the seventh-largest market cap of any publicly traded company, currently valued at over $765 billion. Berkshire Hathaway is highly diversified, ownin... | Eric Cuka owns AbbVie, Alphabet (A shares), Amazon, Apple, Bank of America, Invesco QQQ Trust, Microsoft, Nvidia, SentinelOne, Inc., Snowflake Inc., Tesla, UnitedHealth Group, and Visa. In today's video, I break down the history of the company, discuss what the business owns, compare the stock's performance to the SPDR... | Eric Cuka owns AbbVie, Alphabet (A shares), Amazon, Apple, Bank of America, Invesco QQQ Trust, Microsoft, Nvidia, SentinelOne, Inc., Snowflake Inc., Tesla, UnitedHealth Group, and Visa. The Motley Fool owns and recommends Activision Blizzard, Alphabet (A shares), Amazon, Apple, Berkshire Hathaway (B shares), Meta Platf... | Eric Cuka owns AbbVie, Alphabet (A shares), Amazon, Apple, Bank of America, Invesco QQQ Trust, Microsoft, Nvidia, SentinelOne, Inc., Snowflake Inc., Tesla, UnitedHealth Group, and Visa. See the 10 stocks *Stock Advisor returns as of March 3, 2022 John Mackey, CEO of Whole Foods Market, an Amazon subsidiary, is a member... | Eric Cuka owns AbbVie, Alphabet (A shares), Amazon, Apple, Bank of America, Invesco QQQ Trust, Microsoft, Nvidia, SentinelOne, Inc., Snowflake Inc., Tesla, UnitedHealth Group, and Visa. Berkshire Hathaway is highly diversified, owning companies in various sectors as well as shares of stock in several public companies. ... |
23,501 | 2022-04-05 00:00:00 UTC | 7 Safe Stocks to Buy to Guard Against a Recession | ABBV | https://www.nasdaq.com/articles/7-safe-stocks-to-buy-to-guard-against-a-recession | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
As the chances of a recession keep climbing, the clock’s ticking when it comes to getting your portfolio ready to ride out the continued storms in the markets. Fortunately, it’s not too late to do so by cycling into safe stocks.
These types of high-quality,... | 7 Dividend Stocks to Buy for April With Yields Over 6% Here are seven safe stocks, all ‘A’-rated in my Portfolio Grader, that you should consider adding to your portfolio today: AbbVie (NYSE:ABBV) Bank of Montreal (NYSE:BMO) Equinor (NYSE:EQNR) Pfizer (NYSE:PFE) Prologis (NYSE:PLD) Regeneron Pharmaceuticals (NASDAQ:REG... | 7 Dividend Stocks to Buy for April With Yields Over 6% Here are seven safe stocks, all ‘A’-rated in my Portfolio Grader, that you should consider adding to your portfolio today: AbbVie (NYSE:ABBV) Bank of Montreal (NYSE:BMO) Equinor (NYSE:EQNR) Pfizer (NYSE:PFE) Prologis (NYSE:PLD) Regeneron Pharmaceuticals (NASDAQ:REG... | 7 Dividend Stocks to Buy for April With Yields Over 6% Here are seven safe stocks, all ‘A’-rated in my Portfolio Grader, that you should consider adding to your portfolio today: AbbVie (NYSE:ABBV) Bank of Montreal (NYSE:BMO) Equinor (NYSE:EQNR) Pfizer (NYSE:PFE) Prologis (NYSE:PLD) Regeneron Pharmaceuticals (NASDAQ:REG... | 7 Dividend Stocks to Buy for April With Yields Over 6% Here are seven safe stocks, all ‘A’-rated in my Portfolio Grader, that you should consider adding to your portfolio today: AbbVie (NYSE:ABBV) Bank of Montreal (NYSE:BMO) Equinor (NYSE:EQNR) Pfizer (NYSE:PFE) Prologis (NYSE:PLD) Regeneron Pharmaceuticals (NASDAQ:REG... |
23,502 | 2022-04-05 00:00:00 UTC | Notable Tuesday Option Activity: MRK, ADI, ABBV | ABBV | https://www.nasdaq.com/articles/notable-tuesday-option-activity%3A-mrk-adi-abbv | null | null | Looking at options trading activity among components of the S&P 500 index, there is noteworthy activity today in Merck & Co Inc (Symbol: MRK), where a total volume of 72,349 contracts has been traded thus far today, a contract volume which is representative of approximately 7.2 million underlying shares (given that eve... | Particularly high volume was seen for the $165 strike call option expiring April 14, 2022, with 9,254 contracts trading so far today, representing approximately 925,400 underlying shares of ABBV. Below is a chart showing ADI's trailing twelve month trading history, with the $140 strike highlighted in orange: And AbbVie... | Below is a chart showing ADI's trailing twelve month trading history, with the $140 strike highlighted in orange: And AbbVie Inc (Symbol: ABBV) saw options trading volume of 40,981 contracts, representing approximately 4.1 million underlying shares or approximately 63% of ABBV's average daily trading volume over the pa... | Below is a chart showing ADI's trailing twelve month trading history, with the $140 strike highlighted in orange: And AbbVie Inc (Symbol: ABBV) saw options trading volume of 40,981 contracts, representing approximately 4.1 million underlying shares or approximately 63% of ABBV's average daily trading volume over the pa... | Below is a chart showing ADI's trailing twelve month trading history, with the $140 strike highlighted in orange: And AbbVie Inc (Symbol: ABBV) saw options trading volume of 40,981 contracts, representing approximately 4.1 million underlying shares or approximately 63% of ABBV's average daily trading volume over the pa... |
23,503 | 2022-04-05 00:00:00 UTC | Allergan Reveals Positive Phase 3 Results Of VUITY In Adults With Age-Related Blurry Near Vision | ABBV | https://www.nasdaq.com/articles/allergan-reveals-positive-phase-3-results-of-vuity-in-adults-with-age-related-blurry-near | null | null | (RTTNews) - Allergan, an AbbVie (ABBV) company, announced Tuesday that the Phase 3 VIRGO trial evaluating the safety and efficacy of investigational twice-daily administration of VUITY (pilocarpine HCl ophthalmic solution) 1.25% in adults with presbyopia met its primary efficacy endpoint, improving near vision without ... | (RTTNews) - Allergan, an AbbVie (ABBV) company, announced Tuesday that the Phase 3 VIRGO trial evaluating the safety and efficacy of investigational twice-daily administration of VUITY (pilocarpine HCl ophthalmic solution) 1.25% in adults with presbyopia met its primary efficacy endpoint, improving near vision without ... | (RTTNews) - Allergan, an AbbVie (ABBV) company, announced Tuesday that the Phase 3 VIRGO trial evaluating the safety and efficacy of investigational twice-daily administration of VUITY (pilocarpine HCl ophthalmic solution) 1.25% in adults with presbyopia met its primary efficacy endpoint, improving near vision without ... | (RTTNews) - Allergan, an AbbVie (ABBV) company, announced Tuesday that the Phase 3 VIRGO trial evaluating the safety and efficacy of investigational twice-daily administration of VUITY (pilocarpine HCl ophthalmic solution) 1.25% in adults with presbyopia met its primary efficacy endpoint, improving near vision without ... | (RTTNews) - Allergan, an AbbVie (ABBV) company, announced Tuesday that the Phase 3 VIRGO trial evaluating the safety and efficacy of investigational twice-daily administration of VUITY (pilocarpine HCl ophthalmic solution) 1.25% in adults with presbyopia met its primary efficacy endpoint, improving near vision without ... |
23,504 | 2022-04-04 00:00:00 UTC | AbbVie (ABBV) Stock Sinks As Market Gains: What You Should Know | ABBV | https://www.nasdaq.com/articles/abbvie-abbv-stock-sinks-as-market-gains%3A-what-you-should-know-0 | null | null | In the latest trading session, AbbVie (ABBV) closed at $161.89, marking a -0.49% move from the previous day. This move lagged the S&P 500's daily gain of 0.81%. At the same time, the Dow added 0.3%, and the tech-heavy Nasdaq gained 0.37%.
Heading into today, shares of the drugmaker had gained 8.05% over the past month,... | In the latest trading session, AbbVie (ABBV) closed at $161.89, marking a -0.49% move from the previous day. Wall Street will be looking for positivity from AbbVie as it approaches its next earnings report date. On that day, AbbVie is projected to report earnings of $3.13 per share, which would represent year-over-year... | In the latest trading session, AbbVie (ABBV) closed at $161.89, marking a -0.49% move from the previous day. Wall Street will be looking for positivity from AbbVie as it approaches its next earnings report date. On that day, AbbVie is projected to report earnings of $3.13 per share, which would represent year-over-year... | In the latest trading session, AbbVie (ABBV) closed at $161.89, marking a -0.49% move from the previous day. Wall Street will be looking for positivity from AbbVie as it approaches its next earnings report date. On that day, AbbVie is projected to report earnings of $3.13 per share, which would represent year-over-year... | In the latest trading session, AbbVie (ABBV) closed at $161.89, marking a -0.49% move from the previous day. Wall Street will be looking for positivity from AbbVie as it approaches its next earnings report date. On that day, AbbVie is projected to report earnings of $3.13 per share, which would represent year-over-year... |
23,505 | 2022-04-04 00:00:00 UTC | West Virginia says J&J, drugmakers created 'tsunami' of opioid addiction | ABBV | https://www.nasdaq.com/articles/west-virginia-says-jj-drugmakers-created-tsunami-of-opioid-addiction | null | null | By Dietrich Knauth
April 4 (Reuters) - West Virginia's attorney general on Monday urged a judge to hold Johnson & Johnson JNJ.N, Teva Pharmaceuticals Industries Ltd TEVA.TA, and AbbVie Inc's ABBV.N Allergen liable for causing a "tsunami" of opioid addiction in the state.
Attorney General Patrick Morrisey said during hi... | By Dietrich Knauth April 4 (Reuters) - West Virginia's attorney general on Monday urged a judge to hold Johnson & Johnson JNJ.N, Teva Pharmaceuticals Industries Ltd TEVA.TA, and AbbVie Inc's ABBV.N Allergen liable for causing a "tsunami" of opioid addiction in the state. Attorney General Patrick Morrisey said during hi... | By Dietrich Knauth April 4 (Reuters) - West Virginia's attorney general on Monday urged a judge to hold Johnson & Johnson JNJ.N, Teva Pharmaceuticals Industries Ltd TEVA.TA, and AbbVie Inc's ABBV.N Allergen liable for causing a "tsunami" of opioid addiction in the state. J&J and the three largest U.S. drug distributors... | By Dietrich Knauth April 4 (Reuters) - West Virginia's attorney general on Monday urged a judge to hold Johnson & Johnson JNJ.N, Teva Pharmaceuticals Industries Ltd TEVA.TA, and AbbVie Inc's ABBV.N Allergen liable for causing a "tsunami" of opioid addiction in the state. J&J and the three largest U.S. drug distributors... | By Dietrich Knauth April 4 (Reuters) - West Virginia's attorney general on Monday urged a judge to hold Johnson & Johnson JNJ.N, Teva Pharmaceuticals Industries Ltd TEVA.TA, and AbbVie Inc's ABBV.N Allergen liable for causing a "tsunami" of opioid addiction in the state. There have been a wave of recent settlements ove... |
23,506 | 2022-04-03 00:00:00 UTC | Why Dividend Stocks With Low Payout Ratios Can Be Better Than Those With High Yields | ABBV | https://www.nasdaq.com/articles/why-dividend-stocks-with-low-payout-ratios-can-be-better-than-those-with-high-yields | null | null | Dividend-paying stocks in the S&P 500 have historically outperformed their non-dividend-paying index peers. Dividend-growing companies in the index have performed even better.
So should we buy the highest-yielding dividend-growth stocks in the S&P 500 and call it a day?
Maybe, but there is one last (and less popular) m... | When these high-yield stocks continue to increase their dividend payments over time, they eventually begin to test the limits of their financial security, paying out bigger portions of their earnings. Despite the capital required to maintain their respective operations, these two have not only funded many years of annu... | Low payout ratios, long-term growth potential On the flip side, stocks with low payout ratios offer a balanced approach between returning cash to shareholders and funding future growth. Dividend yield 2.9% 3.0% 1.7% Payout ratio 38.3% 28.6% 22.4% Maximum dividend potential 7.6% 10.5% 7.6% Consecutive years of dividend ... | Low payout ratios, long-term growth potential On the flip side, stocks with low payout ratios offer a balanced approach between returning cash to shareholders and funding future growth. Dividend yield 2.9% 3.0% 1.7% Payout ratio 38.3% 28.6% 22.4% Maximum dividend potential 7.6% 10.5% 7.6% Consecutive years of dividend ... | Furthermore, if a company has a high payout ratio, its dividend growth potential is similarly restricted -- or worse yet, it may need to cut its payout to maintain financial security. The best of both worlds Best yet for investors, a handful of stocks offer relatively high dividend yields and low payout ratios. Dividen... |
23,507 | 2022-04-03 00:00:00 UTC | 3 Dividend Aristocrats to Buy in April | ABBV | https://www.nasdaq.com/articles/3-dividend-aristocrats-to-buy-in-april | null | null | Do you want to know a secret? Many Dividend Aristocrats are overrated by investors.
Sure, it's impressive that these companies have delivered 25 or more consecutive years of dividend increases. However, many of them offer sub-par total returns and dividend yields.
That's not true in every case, though. Here are three D... | The main knock against AbbVie is that sales for its top-selling drug Humira will fall steeply next year with biosimilar rivals entering the U.S. market. AbbVie AbbVie (NYSE: ABBV) isn't merely a Dividend Aristocrat; the company is also a Dividend King with 50 years in a row of dividend increases. However, AbbVie's shar... | AbbVie AbbVie (NYSE: ABBV) isn't merely a Dividend Aristocrat; the company is also a Dividend King with 50 years in a row of dividend increases. Air Products & Chemicals Unlike AbbVie, Air Products & Chemicals (NYSE: APD) has lagged behind the S&P 500 so far this year and over the past three years. However, AbbVie's sh... | AbbVie AbbVie (NYSE: ABBV) isn't merely a Dividend Aristocrat; the company is also a Dividend King with 50 years in a row of dividend increases. See the 10 stocks *Stock Advisor returns as of March 3, 2022 Keith Speights owns AbbVie and Air Products & Chemicals. However, AbbVie's share price has grown faster than its d... | AbbVie AbbVie (NYSE: ABBV) isn't merely a Dividend Aristocrat; the company is also a Dividend King with 50 years in a row of dividend increases. However, AbbVie's share price has grown faster than its dividend has. While the broader market indices have fallen, AbbVie stock is up close to 20%. |
23,508 | 2022-04-03 00:00:00 UTC | 2 Drugmakers Set for Explosive Revenue This Decade | ABBV | https://www.nasdaq.com/articles/2-drugmakers-set-for-explosive-revenue-this-decade | null | null | A blockbuster drug is one that brings in $1 billion or more in annual sales. Every pharmaceutical company aims for that level of sales. That's because these drugs often are the main drivers of the revenue engine. Blockbuster drugs accounted for 56% of the top 20 pharmaceutical companies' drug sales in 2018, according t... | Bristol Myers Squibb and Merck can benefit through sales of their existing oncology drugs and possibly new ones. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market. * They just revealed what they believe are the ten best stocks for investors to buy right now... ... | Blockbuster drugs accounted for 56% of the top 20 pharmaceutical companies' drug sales in 2018, according to a paper in Nature Reviews Drug Discovery. This one shows sales of oncology drugs -- already the top-selling drug category -- continue to grow. After all, the newsletter they have run for over a decade, Motley Fo... | Blockbuster drugs accounted for 56% of the top 20 pharmaceutical companies' drug sales in 2018, according to a paper in Nature Reviews Drug Discovery. Bristol Myers Squibb and Merck can benefit through sales of their existing oncology drugs and possibly new ones. Bristol Myers Squibb has more than 20 new candidates in ... | This one shows sales of oncology drugs -- already the top-selling drug category -- continue to grow. All of this points to increasing revenue for both Bristol Myers Squibb and Merck. * They just revealed what they believe are the ten best stocks for investors to buy right now... and Bristol Myers Squibb wasn't one of t... |
23,509 | 2022-04-01 00:00:00 UTC | 3 Warren Buffett Stocks to Buy in April | ABBV | https://www.nasdaq.com/articles/3-warren-buffett-stocks-to-buy-in-april | null | null | It's April Fools' Day. If Warren Buffett wanted to pull a trick for the ages, he might announce that he's adding $10 billion of several cryptocurrency meme coins to Berkshire Hathaway's (NYSE: BRK.A) (NYSE: BRK.B) portfolio.
I'm not sure that very many people would believe the joke, though. Buffett has been a steadfast... | AbbVie Admittedly, AbbVie (NYSE: ABBV) doesn't rank among Buffett's favorite stocks. However, Buffett has reduced the position in AbbVie quite a bit. Buffett's moves with AbbVie look like a mistake in retrospect. | Keith Speights owns AbbVie, Amazon, Bank of America, and Berkshire Hathaway (B shares). AbbVie Admittedly, AbbVie (NYSE: ABBV) doesn't rank among Buffett's favorite stocks. However, Buffett has reduced the position in AbbVie quite a bit. | AbbVie Admittedly, AbbVie (NYSE: ABBV) doesn't rank among Buffett's favorite stocks. However, Buffett has reduced the position in AbbVie quite a bit. Buffett's moves with AbbVie look like a mistake in retrospect. | AbbVie Admittedly, AbbVie (NYSE: ABBV) doesn't rank among Buffett's favorite stocks. However, Buffett has reduced the position in AbbVie quite a bit. Buffett's moves with AbbVie look like a mistake in retrospect. |
23,510 | 2022-03-31 00:00:00 UTC | Abbvie Inc Shares Near 52-Week High - Market Mover | ABBV | https://www.nasdaq.com/articles/abbvie-inc-shares-near-52-week-high-market-mover-4 | null | null | Abbvie Inc (ABBV) shares closed today at 1.2% below its 52 week high of $164.66, giving the company a market cap of $287B. The stock is currently up 21.4% year-to-date, up 56.9% over the past 12 months, and up 214.3% over the past five years. This week, the Dow Jones Industrial Average fell 0.1%, and the S&P 500 rose 0... | Abbvie Inc (ABBV) shares closed today at 1.2% below its 52 week high of $164.66, giving the company a market cap of $287B. This week, the Dow Jones Industrial Average fell 0.1%, and the S&P 500 rose 0.3%. Beta, a measure of the stock’s volatility relative to the overall market stands at 0.4. | Abbvie Inc (ABBV) shares closed today at 1.2% below its 52 week high of $164.66, giving the company a market cap of $287B. This week, the Dow Jones Industrial Average fell 0.1%, and the S&P 500 rose 0.3%. The stock closed at 0.1% higher than its 5-day moving average, 3.7% higher than its 20-day moving average, and 16.5... | Abbvie Inc (ABBV) shares closed today at 1.2% below its 52 week high of $164.66, giving the company a market cap of $287B. The stock closed at 0.1% higher than its 5-day moving average, 3.7% higher than its 20-day moving average, and 16.5% higher than its 90-day moving average. Market Comparative Performance The compan... | Abbvie Inc (ABBV) shares closed today at 1.2% below its 52 week high of $164.66, giving the company a market cap of $287B. Trading Activity Trading volume this week was 33.0% higher than the 20-day average. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70. |
23,511 | 2022-03-31 00:00:00 UTC | 3 Top Healthcare ETFs to Buy Now and Hold for the Long Haul | ABBV | https://www.nasdaq.com/articles/3-top-healthcare-etfs-to-buy-now-and-hold-for-the-long-haul | null | null | Investing in individual stocks can make some investors nervous due to the amount of necessary research and the risk associated with volatility in the market. One way to quiet those nerves is to place your money into exchange-traded funds that follow a market or sector index and are managed by a financial institution. E... | Moreover, 44% of its total assets are in its top-10 holdings, including Abbott Laboratories, AbbVie, and UnitedHealth, strong companies to hold for the long term. This healthcare ETF also provides investors with an expansive diversification of stocks within the sector, including companies that sell medical products, se... | Moreover, 44% of its total assets are in its top-10 holdings, including Abbott Laboratories, AbbVie, and UnitedHealth, strong companies to hold for the long term. Three healthcare ETFs that provide long-term investors with diversification, along with growth opportunities to outpace the S&P 500, include Vanguard Health ... | Moreover, 44% of its total assets are in its top-10 holdings, including Abbott Laboratories, AbbVie, and UnitedHealth, strong companies to hold for the long term. Three healthcare ETFs that provide long-term investors with diversification, along with growth opportunities to outpace the S&P 500, include Vanguard Health ... | Moreover, 44% of its total assets are in its top-10 holdings, including Abbott Laboratories, AbbVie, and UnitedHealth, strong companies to hold for the long term. Three healthcare ETFs that provide long-term investors with diversification, along with growth opportunities to outpace the S&P 500, include Vanguard Health ... |
23,512 | 2022-03-31 00:00:00 UTC | May 13th Options Now Available For AbbVie (ABBV) | ABBV | https://www.nasdaq.com/articles/may-13th-options-now-available-for-abbvie-abbv | null | null | Investors in AbbVie Inc (Symbol: ABBV) saw new options become available today, for the May 13th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ABBV options chain for the new May 13th contracts and identified one put and one call contract of particular interest.
The put contract ... | Of course, a lot of upside could potentially be left on the table if ABBV shares really soar, which is why looking at the trailing twelve month trading history for AbbVie Inc, as well as studying the business fundamentals becomes important. Below is a chart showing ABBV's trailing twelve month trading history, with the... | Below is a chart showing ABBV's trailing twelve month trading history, with the $165.00 strike highlighted in red: Considering the fact that the $165.00 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the pos... | Below is a chart showing the trailing twelve month trading history for AbbVie Inc, and highlighting in green where the $160.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $165.00 strike price has a current bid of $2.48. Below is a chart showing ABB... | At Stock Options Channel, our YieldBoost formula has looked up and down the ABBV options chain for the new May 13th contracts and identified one put and one call contract of particular interest. Below is a chart showing ABBV's trailing twelve month trading history, with the $165.00 strike highlighted in red: Considerin... |
23,513 | 2022-03-30 00:00:00 UTC | 3 Unstoppable Stocks to Buy in a Bear Market | ABBV | https://www.nasdaq.com/articles/3-unstoppable-stocks-to-buy-in-a-bear-market-0 | null | null | For investors, it may seem difficult to believe that 2022 is only three months old. First, the tech market corrected harshly, and the other major indexes quickly followed. In January, inflation reached a 40-year high and then edged even higher in February. Four projected interest rate hikes have turned rapidly to indic... | For instance, an investor who purchased AbbVie stock three years ago would have paid about $81 per share and now have an effective annual yield of almost 7% -- and a pot of capital gains to boot. AbbVie As the saying goes, "Hair grows even during a recession." AbbVie (NYSE: ABBV) is unlikely to take a significant sales... | AbbVie currently pays investors $1.41 quarterly per share. AbbVie As the saying goes, "Hair grows even during a recession." AbbVie (NYSE: ABBV) is unlikely to take a significant sales hit during an economic downturn as its products are, for the most part, a necessity. | For instance, an investor who purchased AbbVie stock three years ago would have paid about $81 per share and now have an effective annual yield of almost 7% -- and a pot of capital gains to boot. See the 10 stocks *Stock Advisor returns as of March 3, 2022 Bradley Guichard owns AbbVie, Intuitive Surgical, and OReilly A... | AbbVie currently pays investors $1.41 quarterly per share. AbbVie made $9.3 billion in dividend payments in 2021 but earned over $22.7 billion in cash from operations. AbbVie As the saying goes, "Hair grows even during a recession." |
23,514 | 2022-03-30 00:00:00 UTC | Florida reaches $878 million opioid settlements with CVS, Teva, others | ABBV | https://www.nasdaq.com/articles/florida-reaches-%24878-million-opioid-settlements-with-cvs-teva-others | null | null | By Jonathan Stempel and Dietrich Knauth
March 30 (Reuters) - Florida has reached more than $878 million in settlements with CVS Health Corp CVS.N and three drug companies to resolve claims and avert a trial next month over their roles in fueling an opioid epidemic in the third most populous U.S. state.
CVS will pay $48... | CVS will pay $484 million, Teva Pharmaceutical Industries Ltd TEVA.TA will pay $194.8 million, Abbvie Inc's ABBV.N Allergan unit will pay $134.2 million and Endo International Plc ENDP.O will pay $65 million, Florida's attorney general Ashley Moody said in a statement on Wednesday. Abbvie and Endo did not immediately r... | CVS will pay $484 million, Teva Pharmaceutical Industries Ltd TEVA.TA will pay $194.8 million, Abbvie Inc's ABBV.N Allergan unit will pay $134.2 million and Endo International Plc ENDP.O will pay $65 million, Florida's attorney general Ashley Moody said in a statement on Wednesday. Abbvie and Endo did not immediately r... | CVS will pay $484 million, Teva Pharmaceutical Industries Ltd TEVA.TA will pay $194.8 million, Abbvie Inc's ABBV.N Allergan unit will pay $134.2 million and Endo International Plc ENDP.O will pay $65 million, Florida's attorney general Ashley Moody said in a statement on Wednesday. Abbvie and Endo did not immediately r... | CVS will pay $484 million, Teva Pharmaceutical Industries Ltd TEVA.TA will pay $194.8 million, Abbvie Inc's ABBV.N Allergan unit will pay $134.2 million and Endo International Plc ENDP.O will pay $65 million, Florida's attorney general Ashley Moody said in a statement on Wednesday. Abbvie and Endo did not immediately r... |
23,515 | 2022-03-30 00:00:00 UTC | 5 Charts That Show Why Bristol-Myers Squibb Is a No-Brainer Buy | ABBV | https://www.nasdaq.com/articles/5-charts-that-show-why-bristol-myers-squibb-is-a-no-brainer-buy | null | null | Are you looking for a safe investment that you can just buy and forget? One stock that will definitely tick off many check marks for you is Bristol-Myers Squibb (NYSE: BMY). The healthcare giant is worth close to $160 billion, has a proven track record, pays a high dividend, and continues to find ways to grow.
But rath... | The healthcare giant is worth close to $160 billion, has a proven track record, pays a high dividend, and continues to find ways to grow. That diversification makes the business a stable one; through 2025, the company projects that its revenue will grow annually in the low-to-mid-single digits. There is no shortage of ... | Bristol-Myers has multiple drugs that are top 10 in sales No drug or vaccine came close to the revenue Pfizer's COVID-19 vaccine generated last year -- and that isn't likely to change this year, either, especially with a fourth dose possibly on the way. And with gross margins normally above 70%, this is another area of... | And with gross margins normally above 70%, this is another area of strength for Bristol-Myers: BMY Gross Profit Margin (Quarterly) data by YCharts A strong gross margin can help improve profitability and also lead to strong free cash flow, which is demonstrated in the next chart. BMY Free Cash Flow (Annual) data by YCh... | With the free cash flow continuing to come in, the company should have room to make more dividend hikes. BMY Dividend data by YCharts With growth and dividends, investors can get the best of both worlds with a relatively safe stock in Bristol-Myers. Bristol-Myers' robust and diverse business makes this a top stock to b... |
23,516 | 2022-03-29 00:00:00 UTC | XLV, UNH, JNJ, ABBV: Large Inflows Detected at ETF | ABBV | https://www.nasdaq.com/articles/xlv-unh-jnj-abbv%3A-large-inflows-detected-at-etf-0 | null | null | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the The Health Care Select Sector SPDR Fund (Symbol: XLV) where we have detected an approximate $693.2 million dollar inflow -- that's a 1.9% increase week over week in outstanding units (from 2... | Among the largest underlying components of XLV, in trading today UnitedHealth Group Inc (Symbol: UNH) is up about 0.6%, Johnson & Johnson (Symbol: JNJ) is up about 0.1%, and AbbVie Inc (Symbol: ABBV) is higher by about 0.2%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered a... | Among the largest underlying components of XLV, in trading today UnitedHealth Group Inc (Symbol: UNH) is up about 0.6%, Johnson & Johnson (Symbol: JNJ) is up about 0.1%, and AbbVie Inc (Symbol: ABBV) is higher by about 0.2%. For a complete list of holdings, visit the XLV Holdings page » The chart below shows the one ye... | Among the largest underlying components of XLV, in trading today UnitedHealth Group Inc (Symbol: UNH) is up about 0.6%, Johnson & Johnson (Symbol: JNJ) is up about 0.1%, and AbbVie Inc (Symbol: ABBV) is higher by about 0.2%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered a... | Among the largest underlying components of XLV, in trading today UnitedHealth Group Inc (Symbol: UNH) is up about 0.6%, Johnson & Johnson (Symbol: JNJ) is up about 0.1%, and AbbVie Inc (Symbol: ABBV) is higher by about 0.2%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered a... |
23,517 | 2022-03-28 00:00:00 UTC | AbbVie (ABBV) Gains But Lags Market: What You Should Know | ABBV | https://www.nasdaq.com/articles/abbvie-abbv-gains-but-lags-market%3A-what-you-should-know-2 | null | null | AbbVie (ABBV) closed the most recent trading day at $161.97, moving +0.4% from the previous trading session. This move lagged the S&P 500's daily gain of 0.71%. Elsewhere, the Dow gained 0.27%, while the tech-heavy Nasdaq added 0.33%.
Prior to today's trading, shares of the drugmaker had gained 7.88% over the past mont... | For comparison, its industry has an average Forward P/E of 12.83, which means AbbVie is trading at a discount to the group. AbbVie (ABBV) closed the most recent trading day at $161.97, moving +0.4% from the previous trading session. AbbVie will be looking to display strength as it nears its next earnings release. | AbbVie (ABBV) closed the most recent trading day at $161.97, moving +0.4% from the previous trading session. AbbVie will be looking to display strength as it nears its next earnings release. It is also important to note the recent changes to analyst estimates for AbbVie. | AbbVie (ABBV) closed the most recent trading day at $161.97, moving +0.4% from the previous trading session. AbbVie will be looking to display strength as it nears its next earnings release. It is also important to note the recent changes to analyst estimates for AbbVie. | AbbVie (ABBV) closed the most recent trading day at $161.97, moving +0.4% from the previous trading session. AbbVie will be looking to display strength as it nears its next earnings release. It is also important to note the recent changes to analyst estimates for AbbVie. |
23,518 | 2022-03-28 00:00:00 UTC | 3 Warren Buffett Stocks I'd Buy Without Any Hesitation | ABBV | https://www.nasdaq.com/articles/3-warren-buffett-stocks-id-buy-without-any-hesitation | null | null | I'll admit that I've sometimes succumbed to "analysis paralysis" in the past. When faced with an investment decision, I hemmed and hawed for way more time than I should have.
With the current market conditions, there are probably plenty of investors experiencing a similar condition right now. Warren Buffett himself ack... | AbbVie Buffett sold some of Berkshire's stake in AbbVie (NYSE: ABBV) in the fourth quarter of 2021. I think that AbbVie's long-term prospects look good, too. However, AbbVie's management team says it expects to quickly return to solid growth. | AbbVie Buffett sold some of Berkshire's stake in AbbVie (NYSE: ABBV) in the fourth quarter of 2021. I think that AbbVie's long-term prospects look good, too. However, AbbVie's management team says it expects to quickly return to solid growth. | AbbVie Buffett sold some of Berkshire's stake in AbbVie (NYSE: ABBV) in the fourth quarter of 2021. I think that AbbVie's long-term prospects look good, too. However, AbbVie's management team says it expects to quickly return to solid growth. | AbbVie Buffett sold some of Berkshire's stake in AbbVie (NYSE: ABBV) in the fourth quarter of 2021. I think that AbbVie's long-term prospects look good, too. However, AbbVie's management team says it expects to quickly return to solid growth. |
23,519 | 2022-03-26 00:00:00 UTC | Have $1,000? 2 Warren Buffett Stocks to Buy | ABBV | https://www.nasdaq.com/articles/have-%241000-2-warren-buffett-stocks-to-buy-0 | null | null | Whether you're an investor just starting out or one who might have a limited budget, it's a good practice to invest an amount that you're willing to be without in the short term so that you can build for the long term. If $1,000 is that mark for you, these two Warren Buffett-backed stocks could provide the foundation y... | A robust pipeline of drugs combined with a hefty dividend yield of 3.5% that leads most of its big-cap pharma peers makes AbbVie a Buffett-backed stock I'd see no problem investing $1,000 in. AbbVie (NYSE: ABBV) and Verizon Communications (NYSE: VZ) offer innovative products in growing markets, combined with a strategy... | AbbVie (NYSE: ABBV) and Verizon Communications (NYSE: VZ) offer innovative products in growing markets, combined with a strategy that withstands market volatility, to reward investors with long-term gains. AbbVie: Building a pipeline to keep revenue flowing AbbVie is one of the smallest holdings in Buffett's Berkshire ... | AbbVie (NYSE: ABBV) and Verizon Communications (NYSE: VZ) offer innovative products in growing markets, combined with a strategy that withstands market volatility, to reward investors with long-term gains. AbbVie: Building a pipeline to keep revenue flowing AbbVie is one of the smallest holdings in Buffett's Berkshire ... | AbbVie is also seeing positive results from its Allergan acquisition in 2020, which netted the company Botox, contributing nearly $5 billion to total sales in 2021. AbbVie (NYSE: ABBV) and Verizon Communications (NYSE: VZ) offer innovative products in growing markets, combined with a strategy that withstands market vol... |
23,520 | 2022-03-25 00:00:00 UTC | 3 Profitable Passive Income Stocks to Buy for Your Retirement Years | ABBV | https://www.nasdaq.com/articles/3-profitable-passive-income-stocks-to-buy-for-your-retirement-years | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
AbbVie (NYSE:ABBV): The pharma giant has been expanding its portfolio to compensate for the upcoming loss of Humira exclusivity
Chevron Corporation (NYSE:CVX): CVX stock recently hit a record high and the bullish sentiment will likely continue
Cincinnati Fi... | InvestorPlace - Stock Market News, Stock Advice & Trading Tips AbbVie (NYSE:ABBV): The pharma giant has been expanding its portfolio to compensate for the upcoming loss of Humira exclusivity Chevron Corporation (NYSE:CVX): CVX stock recently hit a record high and the bullish sentiment will likely continue Cincinnati Fi... | 6 Blue-Chip Stocks That Will Survive Any Bubble Burst With that information, here are 3 passive income stocks to buy that could see consistent low-risk returns in the long-term: ABBV AbbVie $161.94 CVX Chevron Corporation $166.60 CINF Cincinnati Financial Corporation $136.48 Passive Income Stocks: AbbVie (ABBV) Source:... | InvestorPlace - Stock Market News, Stock Advice & Trading Tips AbbVie (NYSE:ABBV): The pharma giant has been expanding its portfolio to compensate for the upcoming loss of Humira exclusivity Chevron Corporation (NYSE:CVX): CVX stock recently hit a record high and the bullish sentiment will likely continue Cincinnati Fi... | 6 Blue-Chip Stocks That Will Survive Any Bubble Burst With that information, here are 3 passive income stocks to buy that could see consistent low-risk returns in the long-term: ABBV AbbVie $161.94 CVX Chevron Corporation $166.60 CINF Cincinnati Financial Corporation $136.48 Passive Income Stocks: AbbVie (ABBV) Source:... |
23,521 | 2022-03-25 00:00:00 UTC | 1 Green Flag for Eli Lilly Investors in 2022 -- and 1 Red Flag | ABBV | https://www.nasdaq.com/articles/1-green-flag-for-eli-lilly-investors-in-2022-and-1-red-flag | null | null | Pharma giant Eli Lilly & Company (NYSE: LLY) has performed splendidly in the past year, leaving both the broader market and the pharmaceutical industry in the dust. But it's difficult to predict whether the company will continue on its upward trajectory for the rest of the year. Geopolitical tensions, which are already... | But as a result of that run, the drugmaker's shares now look a bit overvalued compared to pharmaceutical industry peers such as AbbVie and Pfizer. Pharma giant Eli Lilly & Company (NYSE: LLY) has performed splendidly in the past year, leaving both the broader market and the pharmaceutical industry in the dust. LLY data... | But as a result of that run, the drugmaker's shares now look a bit overvalued compared to pharmaceutical industry peers such as AbbVie and Pfizer. LLY data by YCharts Green flag: A highly promising pipeline Developing and marketing novel therapies is capital-intensive, but companies that succeed in getting drugs approv... | But as a result of that run, the drugmaker's shares now look a bit overvalued compared to pharmaceutical industry peers such as AbbVie and Pfizer. Red flag: Valuation is a concern The combination of Eli Lilly's exciting pipeline and solid financial results have contributed to an impressive stock market performance in r... | But as a result of that run, the drugmaker's shares now look a bit overvalued compared to pharmaceutical industry peers such as AbbVie and Pfizer. LLY data by YCharts Green flag: A highly promising pipeline Developing and marketing novel therapies is capital-intensive, but companies that succeed in getting drugs approv... |
23,522 | 2022-03-24 00:00:00 UTC | May 6th Options Now Available For AbbVie (ABBV) | ABBV | https://www.nasdaq.com/articles/may-6th-options-now-available-for-abbvie-abbv | null | null | Investors in AbbVie Inc (Symbol: ABBV) saw new options become available today, for the May 6th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ABBV options chain for the new May 6th contracts and identified one put and one call contract of particular interest.
The put contract at... | Of course, a lot of upside could potentially be left on the table if ABBV shares really soar, which is why looking at the trailing twelve month trading history for AbbVie Inc, as well as studying the business fundamentals becomes important. Below is a chart showing ABBV's trailing twelve month trading history, with the... | Below is a chart showing ABBV's trailing twelve month trading history, with the $165.00 strike highlighted in red: Considering the fact that the $165.00 strike represents an approximate 3% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the pos... | Below is a chart showing the trailing twelve month trading history for AbbVie Inc, and highlighting in green where the $150.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $165.00 strike price has a current bid of $1.40. Below is a chart showing ABB... | At Stock Options Channel, our YieldBoost formula has looked up and down the ABBV options chain for the new May 6th contracts and identified one put and one call contract of particular interest. Below is a chart showing ABBV's trailing twelve month trading history, with the $165.00 strike highlighted in red: Considering... |
23,523 | 2022-03-24 00:00:00 UTC | 2 Surging Stocks to Buy to Fight Market Volatility | ABBV | https://www.nasdaq.com/articles/2-surging-stocks-to-buy-to-fight-market-volatility | null | null | Stocks ripped off a solid stretch over the last week that helped many investors breathe a sigh of relief amid the triple threat of higher interest rates, rising energy prices, and geopolitical chaos. The Nasdaq is up about 10% from its March 14 lows, even with Wednesday’s 1.3% drop.
Wall Street appeared to cheer the fa... | AbbVie ABBV AbbVie and its stock price are thriving even as patent protections run out for one of the world’s best-selling drugs, Humira. Biosimilars are currently available outside of the U.S. Thankfully, AbbVie prepared to move forward, in part, through its $63 billion Allergan acquisition that it completed in 2020. ... | Image Source: Zacks Investment Research AbbVie has consistently topped our quarterly EPS estimates and it lands “B” grades across the board for Value, Growth, and Momentum in our Style Scores system. AbbVie ABBV AbbVie and its stock price are thriving even as patent protections run out for one of the world’s best-selli... | Plus, Wall Street is high on the stock, with nine of the 13 brokerage recommendations Zacks has at “Strong Buys,” with nothing below a “Hold.” AbbVie also offers investors a solid dividend payment that it’s continually raised, with the payout up 250% since the inception in 2013. AbbVie ABBV AbbVie and its stock price a... | AbbVie ABBV AbbVie and its stock price are thriving even as patent protections run out for one of the world’s best-selling drugs, Humira. Biosimilars are currently available outside of the U.S. Thankfully, AbbVie prepared to move forward, in part, through its $63 billion Allergan acquisition that it completed in 2020. ... |
23,524 | 2022-03-24 00:00:00 UTC | Texas demands drug companies turn over documents on 'puberty blocking' drugs for children | ABBV | https://www.nasdaq.com/articles/texas-demands-drug-companies-turn-over-documents-on-puberty-blocking-drugs-for-children | null | null | By Dan Whitcomb
March 24 (Reuters) - The Texas attorney general on Thursday ordered drugmakers Abbvie Inc ABBV.N and Endo International ENDP.O to turn over materials related to the sale of puberty blockers to children who believe they are transgender, part of an investigation into their off-label use.
The demand comes ... | By Dan Whitcomb March 24 (Reuters) - The Texas attorney general on Thursday ordered drugmakers Abbvie Inc ABBV.N and Endo International ENDP.O to turn over materials related to the sale of puberty blockers to children who believe they are transgender, part of an investigation into their off-label use. Representatives f... | By Dan Whitcomb March 24 (Reuters) - The Texas attorney general on Thursday ordered drugmakers Abbvie Inc ABBV.N and Endo International ENDP.O to turn over materials related to the sale of puberty blockers to children who believe they are transgender, part of an investigation into their off-label use. Paxton said that ... | By Dan Whitcomb March 24 (Reuters) - The Texas attorney general on Thursday ordered drugmakers Abbvie Inc ABBV.N and Endo International ENDP.O to turn over materials related to the sale of puberty blockers to children who believe they are transgender, part of an investigation into their off-label use. Paxton said that ... | By Dan Whitcomb March 24 (Reuters) - The Texas attorney general on Thursday ordered drugmakers Abbvie Inc ABBV.N and Endo International ENDP.O to turn over materials related to the sale of puberty blockers to children who believe they are transgender, part of an investigation into their off-label use. Paxton said that ... |
23,525 | 2022-03-24 00:00:00 UTC | Pfizer's (PFE) Etrasimod Meets Ulcerative Colitis Study Goals | ABBV | https://www.nasdaq.com/articles/pfizers-pfe-etrasimod-meets-ulcerative-colitis-study-goals | null | null | Pfizer Inc. PFE announced topline data from the phase III ELEVATE UC 12 study, which evaluated its immuno-inflammatory pipeline candidate etrasimod for moderately-to-severely active ulcerative colitis (UC).
The ELEVATE UC 12 study evaluated etrasimod versus placebo over a 12-week treatment period in 354 UC patients who... | Earlier this month, AbbVie received an approval for label expansion from the FDA for its JAK inhibitor drug Rinvoq to address UC indication. The targeted UC market is highly competitive with many companies like AbbVie ABBV and Johnson & Johnson JNJ marketing their own drugs, which utilize different mechanisms of action... | The targeted UC market is highly competitive with many companies like AbbVie ABBV and Johnson & Johnson JNJ marketing their own drugs, which utilize different mechanisms of action to treat the indication. Earlier this month, AbbVie received an approval for label expansion from the FDA for its JAK inhibitor drug Rinvoq ... | The targeted UC market is highly competitive with many companies like AbbVie ABBV and Johnson & Johnson JNJ marketing their own drugs, which utilize different mechanisms of action to treat the indication. Earlier this month, AbbVie received an approval for label expansion from the FDA for its JAK inhibitor drug Rinvoq ... | Earlier this month, AbbVie received an approval for label expansion from the FDA for its JAK inhibitor drug Rinvoq to address UC indication. The targeted UC market is highly competitive with many companies like AbbVie ABBV and Johnson & Johnson JNJ marketing their own drugs, which utilize different mechanisms of action... |
23,526 | 2022-03-22 00:00:00 UTC | AbbVie (ABBV) Stock Sinks As Market Gains: What You Should Know | ABBV | https://www.nasdaq.com/articles/abbvie-abbv-stock-sinks-as-market-gains%3A-what-you-should-know | null | null | In the latest trading session, AbbVie (ABBV) closed at $160.01, marking a -0.02% move from the previous day. This move lagged the S&P 500's daily gain of 1.13%. At the same time, the Dow added 0.74%, and the tech-heavy Nasdaq gained 0.87%.
Prior to today's trading, shares of the drugmaker had gained 11.12% over the pas... | In the latest trading session, AbbVie (ABBV) closed at $160.01, marking a -0.02% move from the previous day. AbbVie will be looking to display strength as it nears its next earnings release. In that report, analysts expect AbbVie to post earnings of $3.13 per share. | In the latest trading session, AbbVie (ABBV) closed at $160.01, marking a -0.02% move from the previous day. AbbVie will be looking to display strength as it nears its next earnings release. In that report, analysts expect AbbVie to post earnings of $3.13 per share. | In the latest trading session, AbbVie (ABBV) closed at $160.01, marking a -0.02% move from the previous day. AbbVie will be looking to display strength as it nears its next earnings release. In that report, analysts expect AbbVie to post earnings of $3.13 per share. | In the latest trading session, AbbVie (ABBV) closed at $160.01, marking a -0.02% move from the previous day. AbbVie is currently a Zacks Rank #3 (Hold). AbbVie will be looking to display strength as it nears its next earnings release. |
23,527 | 2022-03-21 00:00:00 UTC | Rhode island reaches opioid settlements valued at $107 mln | ABBV | https://www.nasdaq.com/articles/rhode-island-reaches-opioid-settlements-valued-at-%24107-mln | null | null | Adds AG quote, Teva comment
March 21 (Reuters) - Rhode Island's attorney general on Monday announced settlements he valued at $107 million against the drugmakers Teva Pharmaceutical Industries TEVA.TA and AbbVie's ABBV.N Allergan unit to resolve claims over their roles in fueling an opioid epidemic in the state.
Attorn... | Adds AG quote, Teva comment March 21 (Reuters) - Rhode Island's attorney general on Monday announced settlements he valued at $107 million against the drugmakers Teva Pharmaceutical Industries TEVA.TA and AbbVie's ABBV.N Allergan unit to resolve claims over their roles in fueling an opioid epidemic in the state. "While... | Adds AG quote, Teva comment March 21 (Reuters) - Rhode Island's attorney general on Monday announced settlements he valued at $107 million against the drugmakers Teva Pharmaceutical Industries TEVA.TA and AbbVie's ABBV.N Allergan unit to resolve claims over their roles in fueling an opioid epidemic in the state. Attorn... | Adds AG quote, Teva comment March 21 (Reuters) - Rhode Island's attorney general on Monday announced settlements he valued at $107 million against the drugmakers Teva Pharmaceutical Industries TEVA.TA and AbbVie's ABBV.N Allergan unit to resolve claims over their roles in fueling an opioid epidemic in the state. Attorn... | Adds AG quote, Teva comment March 21 (Reuters) - Rhode Island's attorney general on Monday announced settlements he valued at $107 million against the drugmakers Teva Pharmaceutical Industries TEVA.TA and AbbVie's ABBV.N Allergan unit to resolve claims over their roles in fueling an opioid epidemic in the state. Attorn... |
23,528 | 2022-03-21 00:00:00 UTC | XLV, UNH, JNJ, ABBV: Large Inflows Detected at ETF | ABBV | https://www.nasdaq.com/articles/xlv-unh-jnj-abbv%3A-large-inflows-detected-at-etf | null | null | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the The Health Care Select Sector SPDR Fund (Symbol: XLV) where we have detected an approximate $705.2 million dollar inflow -- that's a 2.0% increase week over week in outstanding units (from 2... | Among the largest underlying components of XLV, in trading today UnitedHealth Group Inc (Symbol: UNH) is up about 0.3%, Johnson & Johnson (Symbol: JNJ) is up about 0.9%, and AbbVie Inc (Symbol: ABBV) is up by about 0.5%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ET... | Among the largest underlying components of XLV, in trading today UnitedHealth Group Inc (Symbol: UNH) is up about 0.3%, Johnson & Johnson (Symbol: JNJ) is up about 0.9%, and AbbVie Inc (Symbol: ABBV) is up by about 0.5%. For a complete list of holdings, visit the XLV Holdings page » The chart below shows the one year p... | Among the largest underlying components of XLV, in trading today UnitedHealth Group Inc (Symbol: UNH) is up about 0.3%, Johnson & Johnson (Symbol: JNJ) is up about 0.9%, and AbbVie Inc (Symbol: ABBV) is up by about 0.5%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ET... | Among the largest underlying components of XLV, in trading today UnitedHealth Group Inc (Symbol: UNH) is up about 0.3%, Johnson & Johnson (Symbol: JNJ) is up about 0.9%, and AbbVie Inc (Symbol: ABBV) is up by about 0.5%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ET... |
23,529 | 2022-03-21 00:00:00 UTC | Amgen (AMGN) Outperforms Industry This Year So Far: What Next? | ABBV | https://www.nasdaq.com/articles/amgen-amgn-outperforms-industry-this-year-so-far%3A-what-next | null | null | Amgen AMGN has a diverse and growing portfolio of medicines in large therapeutic categories that it expects will help it drive growth through the end of the decade despite a declining pricing environment.
Amgen stock has risen 6% this year so far against a decrease of 12.6% for the industry.
Image Source: Zacks Invest... | Amgen markets Kanjinti (a biosimilar of Roche’s [RHHBY] Herceptin) and Mvasi ( a biosimilar of Roche’s Avastin) in the United States and Amgevita (a biosimilar of AbbVie’s [ABBV] Humira), Kanjinti and Mvasi outside the United States. In the United States, AbbVie’s Humira biosimilar, Amjevita is expected to be launched ... | Amgen markets Kanjinti (a biosimilar of Roche’s [RHHBY] Herceptin) and Mvasi ( a biosimilar of Roche’s Avastin) in the United States and Amgevita (a biosimilar of AbbVie’s [ABBV] Humira), Kanjinti and Mvasi outside the United States. In the United States, AbbVie’s Humira biosimilar, Amjevita is expected to be launched ... | Amgen markets Kanjinti (a biosimilar of Roche’s [RHHBY] Herceptin) and Mvasi ( a biosimilar of Roche’s Avastin) in the United States and Amgevita (a biosimilar of AbbVie’s [ABBV] Humira), Kanjinti and Mvasi outside the United States. In the United States, AbbVie’s Humira biosimilar, Amjevita is expected to be launched ... | Amgen markets Kanjinti (a biosimilar of Roche’s [RHHBY] Herceptin) and Mvasi ( a biosimilar of Roche’s Avastin) in the United States and Amgevita (a biosimilar of AbbVie’s [ABBV] Humira), Kanjinti and Mvasi outside the United States. In the United States, AbbVie’s Humira biosimilar, Amjevita is expected to be launched ... |
23,530 | 2022-03-20 00:00:00 UTC | 5 Unexpected Sources of Retirement Income | ABBV | https://www.nasdaq.com/articles/5-unexpected-sources-of-retirement-income-1 | null | null | If you're thinking about retirement, and you're worried that your expected income may not be enough, here's some good news: There are many possible sources of retirement income, and some of them may be surprises to you.
Here's a look at some ways to generate income in your later years. See which ones make the most sens... | 4.2% AbbVie 3.8% Sanofi 3.8% Chevron 3.3% Pfizer 3.2% Coca-Cola 3% Data source: Yahoo! Selena Maranjian owns AbbVie and Enbridge. By shedding one vehicle, you can collect some cash for it upfront, and then you'll simply save money in the future, not having to pay for insurance, maintenance, and repairs. | 4.2% AbbVie 3.8% Sanofi 3.8% Chevron 3.3% Pfizer 3.2% Coca-Cola 3% Data source: Yahoo! Selena Maranjian owns AbbVie and Enbridge. By shedding one vehicle, you can collect some cash for it upfront, and then you'll simply save money in the future, not having to pay for insurance, maintenance, and repairs. | 4.2% AbbVie 3.8% Sanofi 3.8% Chevron 3.3% Pfizer 3.2% Coca-Cola 3% Data source: Yahoo! Selena Maranjian owns AbbVie and Enbridge. If you're thinking about retirement, and you're worried that your expected income may not be enough, here's some good news: There are many possible sources of retirement income, and some of ... | 4.2% AbbVie 3.8% Sanofi 3.8% Chevron 3.3% Pfizer 3.2% Coca-Cola 3% Data source: Yahoo! Selena Maranjian owns AbbVie and Enbridge. Here's a look at some ways to generate income in your later years. |
23,531 | 2022-03-20 00:00:00 UTC | 3 Dividend Stocks That We'd Buy Without Any Hesitation | ABBV | https://www.nasdaq.com/articles/3-dividend-stocks-that-wed-buy-without-any-hesitation | null | null | Reluctant to jump back into buying stocks right now? That's understandable. While the stock market rebounded somewhat last week, there's still a lot of uncertainty about what's around the corner. However, many stocks are available at attractive valuations. And lower share prices have pushed dividend yields higher in ma... | Here's why they chose AbbVie (NYSE: ABBV), Amgen (NASDAQ: AMGN), and Pfizer (NYSE: PFE). A continuing reign Keith Speights (AbbVie): AbbVie has been a Dividend Aristocrat for years. Not AbbVie -- its dividend yield tops 3.5%. | A continuing reign Keith Speights (AbbVie): AbbVie has been a Dividend Aristocrat for years. Here's why they chose AbbVie (NYSE: ABBV), Amgen (NASDAQ: AMGN), and Pfizer (NYSE: PFE). Not AbbVie -- its dividend yield tops 3.5%. | Here's why they chose AbbVie (NYSE: ABBV), Amgen (NASDAQ: AMGN), and Pfizer (NYSE: PFE). A continuing reign Keith Speights (AbbVie): AbbVie has been a Dividend Aristocrat for years. Not AbbVie -- its dividend yield tops 3.5%. | Not AbbVie -- its dividend yield tops 3.5%. Here's why they chose AbbVie (NYSE: ABBV), Amgen (NASDAQ: AMGN), and Pfizer (NYSE: PFE). A continuing reign Keith Speights (AbbVie): AbbVie has been a Dividend Aristocrat for years. |
23,532 | 2022-03-19 00:00:00 UTC | Could This Be Eli Lilly's Next Blockbuster Drug? | ABBV | https://www.nasdaq.com/articles/could-this-be-eli-lillys-next-blockbuster-drug | null | null | On Feb. 18, Eli Lilly (NYSE: LLY) announced impressive results from its first phase 3 clinical trial of mirikizumab in patients with moderately to severely active ulcerative colitis (UC) who didn't benefit from conventional therapies.
Eli Lilly also stated that data from the second trial would be shared in the first ha... | Although an annual list price for the drug won't be announced until its potential launch, drugs like AbbVie's (NYSE: ABBV) Humira and Johnson & Johnson's (NYSE: JNJ) Stelara could be good gauges for what mirikizumab's annual list price may be. See the 10 stocks *Stock Advisor returns as of March 3, 2022 Kody Kester own... | Although an annual list price for the drug won't be announced until its potential launch, drugs like AbbVie's (NYSE: ABBV) Humira and Johnson & Johnson's (NYSE: JNJ) Stelara could be good gauges for what mirikizumab's annual list price may be. See the 10 stocks *Stock Advisor returns as of March 3, 2022 Kody Kester own... | Although an annual list price for the drug won't be announced until its potential launch, drugs like AbbVie's (NYSE: ABBV) Humira and Johnson & Johnson's (NYSE: JNJ) Stelara could be good gauges for what mirikizumab's annual list price may be. See the 10 stocks *Stock Advisor returns as of March 3, 2022 Kody Kester own... | Although an annual list price for the drug won't be announced until its potential launch, drugs like AbbVie's (NYSE: ABBV) Humira and Johnson & Johnson's (NYSE: JNJ) Stelara could be good gauges for what mirikizumab's annual list price may be. See the 10 stocks *Stock Advisor returns as of March 3, 2022 Kody Kester own... |
23,533 | 2022-03-18 00:00:00 UTC | 3 Top Health Care Stocks To Watch Right Now | ABBV | https://www.nasdaq.com/articles/3-top-health-care-stocks-to-watch-right-now | null | null | Do You Have These Health Care Stocks On Your Watchlist Today?
Health care stocks have long been a popular segment of the stock market among investors. Regardless of geopolitical sentiments or the state of the economy, the industry would still be relevant given its importance to our daily lives. Stocks in the health car... | On Wednesday, AbbVie announced that its RINVOQ (upadacitinib) has received the U.S. Food and Drug Administration (FDA) approval for the treatment of adults with moderately to severely active ulcerative colitis. Health Care Stocks To Watch Today Merck & Co., Inc (NYSE: MRK) AbbVie Inc (NYSE: ABBV) Moderna Inc (NASDAQ: M... | Health Care Stocks To Watch Today Merck & Co., Inc (NYSE: MRK) AbbVie Inc (NYSE: ABBV) Moderna Inc (NASDAQ: MRNA) Merck & Co To kick start the list, we will be looking at the global health care company, Merck & Co. [Read More] Stock Market Today: Dow Jones, S&P 500 Mixed; GameStop (GME) To Launch NFT Marketplace AbbVie... | Health Care Stocks To Watch Today Merck & Co., Inc (NYSE: MRK) AbbVie Inc (NYSE: ABBV) Moderna Inc (NASDAQ: MRNA) Merck & Co To kick start the list, we will be looking at the global health care company, Merck & Co. [Read More] Stock Market Today: Dow Jones, S&P 500 Mixed; GameStop (GME) To Launch NFT Marketplace AbbVie... | Health Care Stocks To Watch Today Merck & Co., Inc (NYSE: MRK) AbbVie Inc (NYSE: ABBV) Moderna Inc (NASDAQ: MRNA) Merck & Co To kick start the list, we will be looking at the global health care company, Merck & Co. [Read More] Stock Market Today: Dow Jones, S&P 500 Mixed; GameStop (GME) To Launch NFT Marketplace AbbVie... |
23,534 | 2022-03-18 00:00:00 UTC | AbbVie's (ABBV) Rinvoq Gets FDA Nod for Ulcerative Colitis | ABBV | https://www.nasdaq.com/articles/abbvies-abbv-rinvoq-gets-fda-nod-for-ulcerative-colitis | null | null | AbbVie Inc. ABBV announced that the FDA approved its promising JAK inhibitor, Rinvoq (upadacitinib), for a new indication on Mar 16. The drug is now approved for the treatment of moderately to severely active ulcerative colitis (“UC”) in adult patients whose disease had an inadequate response or is intolerant to one or... | AbbVie Inc. ABBV announced that the FDA approved its promising JAK inhibitor, Rinvoq (upadacitinib), for a new indication on Mar 16. AbbVie is also seeking a label expansion of Rinvoq to include UC patients in Europe. Ongoing Label Expansion Studies AbbVie is evaluating Rinvoq in several clinical stage studies for addi... | AbbVie Inc. ABBV announced that the FDA approved its promising JAK inhibitor, Rinvoq (upadacitinib), for a new indication on Mar 16. AbbVie is also seeking a label expansion of Rinvoq to include UC patients in Europe. Ongoing Label Expansion Studies AbbVie is evaluating Rinvoq in several clinical stage studies for addi... | AbbVie Inc. ABBV announced that the FDA approved its promising JAK inhibitor, Rinvoq (upadacitinib), for a new indication on Mar 16. AbbVie is also seeking a label expansion of Rinvoq to include UC patients in Europe. Ongoing Label Expansion Studies AbbVie is evaluating Rinvoq in several clinical stage studies for addi... | Ongoing Label Expansion Studies AbbVie is evaluating Rinvoq in several clinical stage studies for additional indications. AbbVie Inc. ABBV announced that the FDA approved its promising JAK inhibitor, Rinvoq (upadacitinib), for a new indication on Mar 16. AbbVie is also seeking a label expansion of Rinvoq to include UC ... |
23,535 | 2022-03-17 00:00:00 UTC | These 2 Stocks Just Hit All-Time Highs | ABBV | https://www.nasdaq.com/articles/these-2-stocks-just-hit-all-time-highs | null | null | The stock market had a big upward move on Wednesday, with investors eventually deciding that the Federal Reserve's stance on interest rates was consistent with what they wanted to see over the long run. Although there's still considerable uncertainty about what 2022 will bring in terms of macroeconomic improvement and ... | AbbVie has largely flown under the radar for many investors, in part because like many drugmakers, it faces the huge challenge of how to replace the revenue from blockbuster treatments that are destined to lose their patent protection. Healthy times at AbbVie Meanwhile, shares of AbbVie (NYSE: ABBV) also hit record lev... | Healthy times at AbbVie Meanwhile, shares of AbbVie (NYSE: ABBV) also hit record levels on Wednesday. AbbVie has largely flown under the radar for many investors, in part because like many drugmakers, it faces the huge challenge of how to replace the revenue from blockbuster treatments that are destined to lose their p... | Healthy times at AbbVie Meanwhile, shares of AbbVie (NYSE: ABBV) also hit record levels on Wednesday. AbbVie has largely flown under the radar for many investors, in part because like many drugmakers, it faces the huge challenge of how to replace the revenue from blockbuster treatments that are destined to lose their p... | Healthy times at AbbVie Meanwhile, shares of AbbVie (NYSE: ABBV) also hit record levels on Wednesday. AbbVie has largely flown under the radar for many investors, in part because like many drugmakers, it faces the huge challenge of how to replace the revenue from blockbuster treatments that are destined to lose their p... |
23,536 | 2022-03-17 00:00:00 UTC | 3 Medical Stocks That Could Double Your Returns in the Long Run | ABBV | https://www.nasdaq.com/articles/3-medical-stocks-that-could-double-your-returns-in-the-long-run | null | null | A market mantra is that past returns are no guarantee of future success. However, the longer your view of a stock, the less that is true. Medical Properties Trust (NYSE: MPW), AbbVie (NYSE: ABBV), and Teladoc Health (NYSE: TDOC) all would have doubled your money, or more, if you had invested in them five years ago, bas... | The key for AbbVie will be how well its portfolio and pipeline perform as revenue from blockbuster immunology drug Humira declines as it comes off patent protection in the United States in 2023. Medical Properties Trust (NYSE: MPW), AbbVie (NYSE: ABBV), and Teladoc Health (NYSE: TDOC) all would have doubled your money,... | Medical Properties Trust (NYSE: MPW), AbbVie (NYSE: ABBV), and Teladoc Health (NYSE: TDOC) all would have doubled your money, or more, if you had invested in them five years ago, based on their total returns. AbbVie AbbVie has increased revenue every year for the past decade. The key for AbbVie will be how well its por... | AbbVie's stock is up more than 12% this year and a $10,000 investment in the company five years would have been worth 28,872.33 as of Monday's close. Medical Properties Trust (NYSE: MPW), AbbVie (NYSE: ABBV), and Teladoc Health (NYSE: TDOC) all would have doubled your money, or more, if you had invested in them five ye... | Medical Properties Trust (NYSE: MPW), AbbVie (NYSE: ABBV), and Teladoc Health (NYSE: TDOC) all would have doubled your money, or more, if you had invested in them five years ago, based on their total returns. AbbVie AbbVie has increased revenue every year for the past decade. The key for AbbVie will be how well its por... |
23,537 | 2022-03-17 00:00:00 UTC | GSK to supply essential medicines to Russia, halt clinical trials | ABBV | https://www.nasdaq.com/articles/gsk-to-supply-essential-medicines-to-russia-halt-clinical-trials | null | null | Adds detail, background
March 17 (Reuters) - Britain's GSK GSK.L will keep supplying essential medicines and vaccines in Russia but halt clinical trials, following sanctions against Moscow for its invasion of Ukraine, joining other drugmakers that have taken similar steps.
The London-listed company will not start any n... | Merck MRK.N, Pfizer PFE.N, Eli Lilly LLY.N, Novartis NOVN.S and Abbvie ABBV.N are also pausing investments or scaling back their businesses in Russia. Adds detail, background March 17 (Reuters) - Britain's GSK GSK.L will keep supplying essential medicines and vaccines in Russia but halt clinical trials, following sanct... | Merck MRK.N, Pfizer PFE.N, Eli Lilly LLY.N, Novartis NOVN.S and Abbvie ABBV.N are also pausing investments or scaling back their businesses in Russia. Adds detail, background March 17 (Reuters) - Britain's GSK GSK.L will keep supplying essential medicines and vaccines in Russia but halt clinical trials, following sanct... | Merck MRK.N, Pfizer PFE.N, Eli Lilly LLY.N, Novartis NOVN.S and Abbvie ABBV.N are also pausing investments or scaling back their businesses in Russia. Adds detail, background March 17 (Reuters) - Britain's GSK GSK.L will keep supplying essential medicines and vaccines in Russia but halt clinical trials, following sanct... | Merck MRK.N, Pfizer PFE.N, Eli Lilly LLY.N, Novartis NOVN.S and Abbvie ABBV.N are also pausing investments or scaling back their businesses in Russia. Adds detail, background March 17 (Reuters) - Britain's GSK GSK.L will keep supplying essential medicines and vaccines in Russia but halt clinical trials, following sanct... |
23,538 | 2022-03-17 00:00:00 UTC | These 5 Dividend Stocks Have Generated Double-Digit Returns for Me So Far This Year | ABBV | https://www.nasdaq.com/articles/these-5-dividend-stocks-have-generated-double-digit-returns-for-me-so-far-this-year | null | null | Near the end of World War II, the legendary crooner Bing Crosby and the Andrews Sisters had a hit song that included the lyrics:
You got to ac-cen-tu-ate the positive,
E-lim-i-nate the negative,
And latch on to the affirmative.
Don't mess with Mr. In-between.
Unfortunately, there are a lot of negatives for investors ri... | Many investors have focused primarily on the bleak outlook for Humira, AbbVie's top-selling drug that will lose U.S. exclusivity next year. Bristol Myers Squibb AbbVie isn't the only big pharmaceutical stock in my portfolio that's performing well this year. AbbVie I've proclaimed in the past that AbbVie (NYSE: ABBV) is... | See the 10 stocks *Stock Advisor returns as of March 3, 2022 Keith Speights owns AbbVie, Bristol Myers Squibb, Brookfield Renewable Corporation Inc., Brookfield Renewable Partners L.P., and Devon Energy. AbbVie I've proclaimed in the past that AbbVie (NYSE: ABBV) is a better stock than many investors might think. And A... | See the 10 stocks *Stock Advisor returns as of March 3, 2022 Keith Speights owns AbbVie, Bristol Myers Squibb, Brookfield Renewable Corporation Inc., Brookfield Renewable Partners L.P., and Devon Energy. AbbVie I've proclaimed in the past that AbbVie (NYSE: ABBV) is a better stock than many investors might think. And A... | But that could also be true for Devon, Brookfield Renewable, and AbbVie. See the 10 stocks *Stock Advisor returns as of March 3, 2022 Keith Speights owns AbbVie, Bristol Myers Squibb, Brookfield Renewable Corporation Inc., Brookfield Renewable Partners L.P., and Devon Energy. AbbVie I've proclaimed in the past that Abb... |
23,539 | 2022-03-17 00:00:00 UTC | Want $1 Million in Retirement? Invest $150,000 in These 3 Stocks and Wait a Decade | ABBV | https://www.nasdaq.com/articles/want-%241-million-in-retirement-invest-%24150000-in-these-3-stocks-and-wait-a-decade | null | null | The last decade before retirement is when many people put their wealth-building efforts into overdrive to get ready for their golden years. However, it's important to manage your risk carefully, as a catastrophic misstep could be hard to recover from when you're close to retirement.
Investing a large sum like $150,000 ... | Abbott Labs The healthcare conglomerate has gone through some changes since spinning its pharmaceutical business out as AbbVie almost a decade ago. Abbott also has a storied dividend history that goes back decades before its split with AbbVie. Investing a large sum like $150,000 into each of these three healthcare name... | Abbott Labs The healthcare conglomerate has gone through some changes since spinning its pharmaceutical business out as AbbVie almost a decade ago. Abbott also has a storied dividend history that goes back decades before its split with AbbVie. Today, Abbott Labs (NYSE: ABT) is positioned primarily in consumer products,... | Abbott Labs The healthcare conglomerate has gone through some changes since spinning its pharmaceutical business out as AbbVie almost a decade ago. Abbott also has a storied dividend history that goes back decades before its split with AbbVie. Pharmaceutical companies live and die by their product pipelines, and Pfizer... | Abbott Labs The healthcare conglomerate has gone through some changes since spinning its pharmaceutical business out as AbbVie almost a decade ago. Abbott also has a storied dividend history that goes back decades before its split with AbbVie. Investors also get the benefit of a dividend that yields 3.2%, so the ingred... |
23,540 | 2022-03-16 00:00:00 UTC | Merck pauses Russia investments, to supply essential medicines | ABBV | https://www.nasdaq.com/articles/merck-pauses-russia-investments-to-supply-essential-medicines | null | null | Adds details, background
March 16 (Reuters) - Drugmaker Merck and Co MRK.N said on Wednesday it would not make further investments in Russia, but continue to supply life-saving medicines and vaccines to the country.
Merck joins a growing list of drugmakers, including Pfizer Inc PFE.N, Eli Lilly LLY.N, Novartis NOVN.S a... | Merck joins a growing list of drugmakers, including Pfizer Inc PFE.N, Eli Lilly LLY.N, Novartis NOVN.S and Abbvie Inc ABBV.N, which are pausing investments or scaling back their business in Russia after Moscow's invasion of Ukraine. Adds details, background March 16 (Reuters) - Drugmaker Merck and Co MRK.N said on Wedn... | Merck joins a growing list of drugmakers, including Pfizer Inc PFE.N, Eli Lilly LLY.N, Novartis NOVN.S and Abbvie Inc ABBV.N, which are pausing investments or scaling back their business in Russia after Moscow's invasion of Ukraine. Adds details, background March 16 (Reuters) - Drugmaker Merck and Co MRK.N said on Wedn... | Merck joins a growing list of drugmakers, including Pfizer Inc PFE.N, Eli Lilly LLY.N, Novartis NOVN.S and Abbvie Inc ABBV.N, which are pausing investments or scaling back their business in Russia after Moscow's invasion of Ukraine. Adds details, background March 16 (Reuters) - Drugmaker Merck and Co MRK.N said on Wedn... | Merck joins a growing list of drugmakers, including Pfizer Inc PFE.N, Eli Lilly LLY.N, Novartis NOVN.S and Abbvie Inc ABBV.N, which are pausing investments or scaling back their business in Russia after Moscow's invasion of Ukraine. Adds details, background March 16 (Reuters) - Drugmaker Merck and Co MRK.N said on Wedn... |
23,541 | 2022-03-16 00:00:00 UTC | AbbVie (ABBV) Gains But Lags Market: What You Should Know | ABBV | https://www.nasdaq.com/articles/abbvie-abbv-gains-but-lags-market%3A-what-you-should-know-1 | null | null | AbbVie (ABBV) closed the most recent trading day at $156.05, moving +0.11% from the previous trading session. This change lagged the S&P 500's 2.24% gain on the day. Elsewhere, the Dow gained 1.55%, while the tech-heavy Nasdaq added 0.5%.
Coming into today, shares of the drugmaker had gained 7.68% in the past month. In... | AbbVie (ABBV) closed the most recent trading day at $156.05, moving +0.11% from the previous trading session. AbbVie will be looking to display strength as it nears its next earnings release. Any recent changes to analyst estimates for AbbVie should also be noted by investors. | AbbVie (ABBV) closed the most recent trading day at $156.05, moving +0.11% from the previous trading session. AbbVie will be looking to display strength as it nears its next earnings release. Any recent changes to analyst estimates for AbbVie should also be noted by investors. | AbbVie (ABBV) closed the most recent trading day at $156.05, moving +0.11% from the previous trading session. AbbVie will be looking to display strength as it nears its next earnings release. Any recent changes to analyst estimates for AbbVie should also be noted by investors. | AbbVie (ABBV) closed the most recent trading day at $156.05, moving +0.11% from the previous trading session. AbbVie will be looking to display strength as it nears its next earnings release. Any recent changes to analyst estimates for AbbVie should also be noted by investors. |
23,542 | 2022-03-16 00:00:00 UTC | Top Stock Market News For Today March 16, 2022 | ABBV | https://www.nasdaq.com/articles/top-stock-market-news-for-today-march-16-2022 | null | null | Stock Market Futures Gain Ahead Of Federal Reserve’s Latest Update On Monetary Policy
U.S. stock futures are in the green in early morning trading at the midweek mark. This seems to be the case as investors respond to a slightly lower than expected read from February’s producer price index (PPI). In brief, the PPI rose... | 4 To Watch This Week AbbVie In Focus As Shares Trade At Record Highs Following Numerous Positive Developments AbbVie (NYSE: ABBV) seems to be in the midst of a hot streak in the stock market now. Evidently, ABBV stock is currently trading at around record levels. By and large, these gains follow a string of operational... | 4 To Watch This Week AbbVie In Focus As Shares Trade At Record Highs Following Numerous Positive Developments AbbVie (NYSE: ABBV) seems to be in the midst of a hot streak in the stock market now. Evidently, ABBV stock is currently trading at around record levels. By and large, these gains follow a string of operational... | 4 To Watch This Week AbbVie In Focus As Shares Trade At Record Highs Following Numerous Positive Developments AbbVie (NYSE: ABBV) seems to be in the midst of a hot streak in the stock market now. Evidently, ABBV stock is currently trading at around record levels. By and large, these gains follow a string of operational... | 4 To Watch This Week AbbVie In Focus As Shares Trade At Record Highs Following Numerous Positive Developments AbbVie (NYSE: ABBV) seems to be in the midst of a hot streak in the stock market now. Evidently, ABBV stock is currently trading at around record levels. By and large, these gains follow a string of operational... |
23,543 | 2022-03-16 00:00:00 UTC | ABBV Crosses Above Average Analyst Target | ABBV | https://www.nasdaq.com/articles/abbv-crosses-above-average-analyst-target | null | null | In recent trading, shares of AbbVie Inc (Symbol: ABBV) have crossed above the average analyst 12-month target price of $153.54, changing hands for $155.88/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a... | In recent trading, shares of AbbVie Inc (Symbol: ABBV) have crossed above the average analyst 12-month target price of $153.54, changing hands for $155.88/share. But the whole reason to look at the average ABBV price target in the first place is to tap into a "wisdom of crowds" effort, putting together the contribution... | In recent trading, shares of AbbVie Inc (Symbol: ABBV) have crossed above the average analyst 12-month target price of $153.54, changing hands for $155.88/share. But the whole reason to look at the average ABBV price target in the first place is to tap into a "wisdom of crowds" effort, putting together the contribution... | There are 13 different analyst targets within the Zacks coverage universe contributing to that average for AbbVie Inc, but the average is just that — a mathematical average. And so with ABBV crossing above that average target price of $153.54/share, investors in ABBV have been given a good signal to spend fresh time as... | There are 13 different analyst targets within the Zacks coverage universe contributing to that average for AbbVie Inc, but the average is just that — a mathematical average. In recent trading, shares of AbbVie Inc (Symbol: ABBV) have crossed above the average analyst 12-month target price of $153.54, changing hands for... |
23,544 | 2022-03-15 00:00:00 UTC | 3 Top Stock Trades for This Week | ABBV | https://www.nasdaq.com/articles/3-top-stock-trades-for-this-week | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
For this week’s top stock trades, we’re focusing on strength. And I’m not taking the easy route by jumping on the commodity train either. Instead, I’m offering up two healthcare companies and one blue-chip industrial stock.
I could have given healthcare a c... | Here are the picks: Bristol-Myers Squibb (NYSE:BMY) Abbvie (NASDAQ:ABBV) Deere & Co (NYSE:DE) As always, I’ll share my preferred way to play using stock options. Abbvie (ABBV) Source: The thinkorswim® platform from TD Ameritrade Abbvie shares have gained ground nearly every week this year. 7 Cheap Stocks to Buy If You ... | Here are the picks: Bristol-Myers Squibb (NYSE:BMY) Abbvie (NASDAQ:ABBV) Deere & Co (NYSE:DE) As always, I’ll share my preferred way to play using stock options. Abbvie (ABBV) Source: The thinkorswim® platform from TD Ameritrade Abbvie shares have gained ground nearly every week this year. Top Stock Trades for the Week... | Here are the picks: Bristol-Myers Squibb (NYSE:BMY) Abbvie (NASDAQ:ABBV) Deere & Co (NYSE:DE) As always, I’ll share my preferred way to play using stock options. Abbvie (ABBV) Source: The thinkorswim® platform from TD Ameritrade Abbvie shares have gained ground nearly every week this year. InvestorPlace - Stock Market ... | Here are the picks: Bristol-Myers Squibb (NYSE:BMY) Abbvie (NASDAQ:ABBV) Deere & Co (NYSE:DE) As always, I’ll share my preferred way to play using stock options. Abbvie (ABBV) Source: The thinkorswim® platform from TD Ameritrade Abbvie shares have gained ground nearly every week this year. 7 Cheap Stocks to Buy If You ... |
23,545 | 2022-03-15 00:00:00 UTC | AbbVie, Scripps Join Hands To Develop Direct-acting Antiviral Treatments For Covid-19 | ABBV | https://www.nasdaq.com/articles/abbvie-scripps-join-hands-to-develop-direct-acting-antiviral-treatments-for-covid-19 | null | null | (RTTNews) - AbbVie (ABBV) and Scripps Research, a drug discovery institute, on Tuesday announced a collaboration to develop potential novel, direct-acting antiviral treatments for Covid-19.
Tom Hudson, Chief Scientific Officer of AbbVie, said: "…We are committed to bringing differentiated, next generation oral antivira... | (RTTNews) - AbbVie (ABBV) and Scripps Research, a drug discovery institute, on Tuesday announced a collaboration to develop potential novel, direct-acting antiviral treatments for Covid-19. Tom Hudson, Chief Scientific Officer of AbbVie, said: "…We are committed to bringing differentiated, next generation oral antivira... | (RTTNews) - AbbVie (ABBV) and Scripps Research, a drug discovery institute, on Tuesday announced a collaboration to develop potential novel, direct-acting antiviral treatments for Covid-19. Tom Hudson, Chief Scientific Officer of AbbVie, said: "…We are committed to bringing differentiated, next generation oral antivira... | Tom Hudson, Chief Scientific Officer of AbbVie, said: "…We are committed to bringing differentiated, next generation oral antiviral treatments to patients and ensuring broad access to address the diverse treatment needs around the world." (RTTNews) - AbbVie (ABBV) and Scripps Research, a drug discovery institute, on Tu... | (RTTNews) - AbbVie (ABBV) and Scripps Research, a drug discovery institute, on Tuesday announced a collaboration to develop potential novel, direct-acting antiviral treatments for Covid-19. Tom Hudson, Chief Scientific Officer of AbbVie, said: "…We are committed to bringing differentiated, next generation oral antivira... |
23,546 | 2022-03-14 00:00:00 UTC | AbbVie (ABBV) Inks Deal for Neuropsychiatric Conditions | ABBV | https://www.nasdaq.com/articles/abbvie-abbv-inks-deal-for-neuropsychiatric-conditions | null | null | AbbVie, Inc. ABBV announced that it has entered into a new collaboration agreement with Hungary-based Gedeon Richter to research, develop and commercialize novel dopamine receptor modulators for the potential treatment of neuropsychiatric indications.
Both companies will jointly finance pre-clinical and clinical R&D ac... | AbbVie, Inc. ABBV announced that it has entered into a new collaboration agreement with Hungary-based Gedeon Richter to research, develop and commercialize novel dopamine receptor modulators for the potential treatment of neuropsychiatric indications. While Venclexta is marketed outside the United States solely by AbbV... | AbbVie Inc. Price AbbVie Inc. price | AbbVie Inc. Quote Zacks Rank & Stock to Consider AbbVie currently carries a Zacks Rank #3 (Hold). AbbVie, Inc. ABBV announced that it has entered into a new collaboration agreement with Hungary-based Gedeon Richter to research, develop and commercialize novel dopamine receptor modu... | Per the terms of the deal, AbbVie will receive worldwide commercial rights to any drug developed under the collaboration, except for regions like Europe, Russia, other CIS countries and Vietnam where the drug will be marketed by Richter. AbbVie Inc. Price AbbVie Inc. price | AbbVie Inc. Quote Zacks Rank & Stock to Cons... | AbbVie, Inc. ABBV announced that it has entered into a new collaboration agreement with Hungary-based Gedeon Richter to research, develop and commercialize novel dopamine receptor modulators for the potential treatment of neuropsychiatric indications. Per the terms of the deal, AbbVie will receive worldwide commercial ... |
23,547 | 2022-03-14 00:00:00 UTC | AbbVie a Top Ranked SAFE Dividend Stock With 3.8% Yield (ABBV) | ABBV | https://www.nasdaq.com/articles/abbvie-a-top-ranked-safe-dividend-stock-with-3.8-yield-abbv | null | null | AbbVie Inc (Symbol: ABBV) has been named to the Dividend Channel ''S.A.F.E. 25'' list, signifying a stock with above-average ''DividendRank'' statistics including a strong 3.8% yield, as well as a superb track record of at least two decades of dividend growth, according to the most recent ''DividendRank'' report.
Accor... | Below is a long-term dividend history chart for ABBV, which the report stressed as being of key importance. ABBV operates in the Drugs & Pharmaceuticals sector, among companies like Pfizer Inc (PFE), and Eli Lilly (LLY). AbbVie Inc (Symbol: ABBV) has been named to the Dividend Channel ''S.A.F.E. | AbbVie Inc (Symbol: ABBV) made the "Dividend Channel S.A.F.E. AbbVie Inc (Symbol: ABBV) has been named to the Dividend Channel ''S.A.F.E. According to the ETF Finder at ETF Channel, AbbVie Inc is a member of the iShares S&P 1500 Index ETF (ITOT), and is also an underlying holding representing 1.96% of the SPDR S&P Divi... | According to the ETF Finder at ETF Channel, AbbVie Inc is a member of the iShares S&P 1500 Index ETF (ITOT), and is also an underlying holding representing 1.96% of the SPDR S&P Dividend ETF (SDY), which holds $398,705,673 worth of ABBV shares. AbbVie Inc (Symbol: ABBV) has been named to the Dividend Channel ''S.A.F.E.... | AbbVie Inc (Symbol: ABBV) has been named to the Dividend Channel ''S.A.F.E. According to the ETF Finder at ETF Channel, AbbVie Inc is a member of the iShares S&P 1500 Index ETF (ITOT), and is also an underlying holding representing 1.96% of the SPDR S&P Dividend ETF (SDY), which holds $398,705,673 worth of ABBV shares.... |
23,548 | 2022-03-11 00:00:00 UTC | AbbVie's (ABBV) Qulipta Meets Chronic Migraine Study Endpoints | ABBV | https://www.nasdaq.com/articles/abbvies-abbv-qulipta-meets-chronic-migraine-study-endpoints | null | null | AbbVie ABBV announced that the phase III study — PROGRESS — evaluating its oral calcitonin gene-related peptide (“CGRP”) receptor antagonist, Qulipta (atogepant) — as a preventive treatment for chronic migraine in adults met all primary and secondary endpoints.
Please note that Qulipta received the first FDA approval i... | AbbVie ABBV announced that the phase III study — PROGRESS — evaluating its oral calcitonin gene-related peptide (“CGRP”) receptor antagonist, Qulipta (atogepant) — as a preventive treatment for chronic migraine in adults met all primary and secondary endpoints. Shares of AbbVie have gained 10.1% so far this year agains... | AbbVie ABBV announced that the phase III study — PROGRESS — evaluating its oral calcitonin gene-related peptide (“CGRP”) receptor antagonist, Qulipta (atogepant) — as a preventive treatment for chronic migraine in adults met all primary and secondary endpoints. Shares of AbbVie have gained 10.1% so far this year agains... | AbbVie is the only company to offer three products across the full spectrum of migraine treatment, including preventive therapies for chronic and episodic migraine, as well as acute treatment for migraine attacks. AbbVie ABBV announced that the phase III study — PROGRESS — evaluating its oral calcitonin gene-related pe... | AbbVie ABBV announced that the phase III study — PROGRESS — evaluating its oral calcitonin gene-related peptide (“CGRP”) receptor antagonist, Qulipta (atogepant) — as a preventive treatment for chronic migraine in adults met all primary and secondary endpoints. Shares of AbbVie have gained 10.1% so far this year agains... |
23,549 | 2022-03-11 00:00:00 UTC | Pharma Stock Roundup: PFE, SNY, ABBV's Pipeline Updates, BAYRY's Unit Sale | ABBV | https://www.nasdaq.com/articles/pharma-stock-roundup%3A-pfe-sny-abbvs-pipeline-updates-bayrys-unit-sale | null | null | This week, Pfizer PFE initiated a pediatric study on its new oral antiviral pill for COVID-19, Paxlovid. AbbVie’s ABBV migraine drug, Qulipta met the primary endpoint in a late-stage chronic migraine study. Sanofi’s SNY hemophilia A candidate, efanesoctocog alfa met the primary and key secondary endpoints in a pivotal ... | Qulipta was approved for the preventive treatment of episodic migraine in adults in September AbbVie announced the resolution of its litigation with Alvotech over U.S. patents for its rheumatoid arthritis drug, Humira. AbbVie’s ABBV migraine drug, Qulipta met the primary endpoint in a late-stage chronic migraine study.... | AbbVie Qulipta Succeeds in Chronic Migraine Study: AbbVie’s phase III study evaluating its newly approved CGRP receptor antagonist, Qulipta (atogepant), for chronic migraine prevention met its primary endpoint of a statistically significant reduction from baseline in mean monthly migraine days, compared to placebo, for... | AbbVie Qulipta Succeeds in Chronic Migraine Study: AbbVie’s phase III study evaluating its newly approved CGRP receptor antagonist, Qulipta (atogepant), for chronic migraine prevention met its primary endpoint of a statistically significant reduction from baseline in mean monthly migraine days, compared to placebo, for... | AbbVie’s ABBV migraine drug, Qulipta met the primary endpoint in a late-stage chronic migraine study. AbbVie Qulipta Succeeds in Chronic Migraine Study: AbbVie’s phase III study evaluating its newly approved CGRP receptor antagonist, Qulipta (atogepant), for chronic migraine prevention met its primary endpoint of a sta... |
23,550 | 2022-03-11 00:00:00 UTC | AbbVie, Gedeon To Develop Dopamine Receptor Modulators For Neuropsychiatric Diseases Treatment | ABBV | https://www.nasdaq.com/articles/abbvie-gedeon-to-develop-dopamine-receptor-modulators-for-neuropsychiatric-diseases | null | null | (RTTNews) - AbbVie (ABBV) and Gedeon Richter Plc. have collaborated to research, develop and commercialize novel dopamine receptor modulators for the potential treatment of neuropsychiatric diseases, AbbVie said in a statement.
The collaboration is based on the results of preclinical research carried out by Richter and... | have collaborated to research, develop and commercialize novel dopamine receptor modulators for the potential treatment of neuropsychiatric diseases, AbbVie said in a statement. AbbVie and Richter have collaborated for 15 years on Central Nervous System projects, including globally launched products such as cariprazine... | have collaborated to research, develop and commercialize novel dopamine receptor modulators for the potential treatment of neuropsychiatric diseases, AbbVie said in a statement. (RTTNews) - AbbVie (ABBV) and Gedeon Richter Plc. AbbVie and Richter have collaborated for 15 years on Central Nervous System projects, includ... | have collaborated to research, develop and commercialize novel dopamine receptor modulators for the potential treatment of neuropsychiatric diseases, AbbVie said in a statement. AbbVie and Richter have collaborated for 15 years on Central Nervous System projects, including globally launched products such as cariprazine... | (RTTNews) - AbbVie (ABBV) and Gedeon Richter Plc. have collaborated to research, develop and commercialize novel dopamine receptor modulators for the potential treatment of neuropsychiatric diseases, AbbVie said in a statement. AbbVie and Richter have collaborated for 15 years on Central Nervous System projects, includ... |
23,551 | 2022-03-10 00:00:00 UTC | Notable Thursday Option Activity: PTLO, ABBV, UI | ABBV | https://www.nasdaq.com/articles/notable-thursday-option-activity%3A-ptlo-abbv-ui | null | null | Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Portillos Inc - Class A (Symbol: PTLO), where a total of 2,919 contracts have traded so far, representing approximately 291,900 underlying shares. That amounts to about 42.7% of PTLO's average daily trading volu... | Particularly high volume was seen for the $155 strike call option expiring April 14, 2022, with 4,152 contracts trading so far today, representing approximately 415,200 underlying shares of ABBV. Below is a chart showing PTLO's trailing twelve month trading history, with the $25 strike highlighted in orange: AbbVie Inc... | Below is a chart showing PTLO's trailing twelve month trading history, with the $25 strike highlighted in orange: AbbVie Inc (Symbol: ABBV) options are showing a volume of 33,495 contracts thus far today. That number of contracts represents approximately 3.3 million underlying shares, working out to a sizeable 41.7% of... | Particularly high volume was seen for the $155 strike call option expiring April 14, 2022, with 4,152 contracts trading so far today, representing approximately 415,200 underlying shares of ABBV. Below is a chart showing UI's trailing twelve month trading history, with the $210 strike highlighted in orange: For the var... | Below is a chart showing UI's trailing twelve month trading history, with the $210 strike highlighted in orange: For the various different available expirations for PTLO options, ABBV options, or UI options, visit StockOptionsChannel.com. Below is a chart showing PTLO's trailing twelve month trading history, with the $... |
23,552 | 2022-03-10 00:00:00 UTC | AbbVie: Phase 3 Study With Atogepant In Adult Patients With Chronic Migraine Meets Primary Endpoint | ABBV | https://www.nasdaq.com/articles/abbvie%3A-phase-3-study-with-atogepant-in-adult-patients-with-chronic-migraine-meets-primary | null | null | (RTTNews) - AbbVie (ABBV) said the phase 3 PROGRESS trial evaluating atogepant for the preventive treatment of chronic migraine in adults, met its primary endpoint of statistically significant reduction from baseline in mean monthly migraine days compared to placebo, for both the 60 mg once daily and 30 mg twice daily ... | (RTTNews) - AbbVie (ABBV) said the phase 3 PROGRESS trial evaluating atogepant for the preventive treatment of chronic migraine in adults, met its primary endpoint of statistically significant reduction from baseline in mean monthly migraine days compared to placebo, for both the 60 mg once daily and 30 mg twice daily ... | (RTTNews) - AbbVie (ABBV) said the phase 3 PROGRESS trial evaluating atogepant for the preventive treatment of chronic migraine in adults, met its primary endpoint of statistically significant reduction from baseline in mean monthly migraine days compared to placebo, for both the 60 mg once daily and 30 mg twice daily ... | (RTTNews) - AbbVie (ABBV) said the phase 3 PROGRESS trial evaluating atogepant for the preventive treatment of chronic migraine in adults, met its primary endpoint of statistically significant reduction from baseline in mean monthly migraine days compared to placebo, for both the 60 mg once daily and 30 mg twice daily ... | (RTTNews) - AbbVie (ABBV) said the phase 3 PROGRESS trial evaluating atogepant for the preventive treatment of chronic migraine in adults, met its primary endpoint of statistically significant reduction from baseline in mean monthly migraine days compared to placebo, for both the 60 mg once daily and 30 mg twice daily ... |
23,553 | 2022-03-10 00:00:00 UTC | 7 Drug Stocks to Consider After the Viatris Plunge | ABBV | https://www.nasdaq.com/articles/7-drug-stocks-to-consider-after-the-viatris-plunge | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Until recently, Viatris (NASDAQ:VTRS) was considered a value play among drug stocks. But after its recent earnings report, and announced sale of a key asset? The generic drug maker has been deemed a “value trap,” and has experienced a sharp plunge in price.... | Yet with Humira sales still solid, and as two of its immunology drugs (Skyrizi and Rinvoq) perform well, the market’s back to focusing more on AbbVie’s positives than its negatives. 8 Strong Uptrend Stocks to Buy on the Next Dip Consider these seven well-known drug stocks, all of which are good value in what’s still a ... | 8 Strong Uptrend Stocks to Buy on the Next Dip Consider these seven well-known drug stocks, all of which are good value in what’s still a pricey market: AbbVie (NYSE:ABBV) Bristol-Myers Squibb (NYSE:BMY) GlaxoSmithKline (NYSE:GSK) Johnson & Johnson (NYSE:JNJ) Merck (NYSE:MRK) Novartis (NYSE:NVS) Pfizer (NYSE:PFE) Drug ... | 8 Strong Uptrend Stocks to Buy on the Next Dip Consider these seven well-known drug stocks, all of which are good value in what’s still a pricey market: AbbVie (NYSE:ABBV) Bristol-Myers Squibb (NYSE:BMY) GlaxoSmithKline (NYSE:GSK) Johnson & Johnson (NYSE:JNJ) Merck (NYSE:MRK) Novartis (NYSE:NVS) Pfizer (NYSE:PFE) Drug ... | 8 Strong Uptrend Stocks to Buy on the Next Dip Consider these seven well-known drug stocks, all of which are good value in what’s still a pricey market: AbbVie (NYSE:ABBV) Bristol-Myers Squibb (NYSE:BMY) GlaxoSmithKline (NYSE:GSK) Johnson & Johnson (NYSE:JNJ) Merck (NYSE:MRK) Novartis (NYSE:NVS) Pfizer (NYSE:PFE) Drug ... |
23,554 | 2022-03-09 00:00:00 UTC | 7 Dividend Stocks to Finance Your Golden Years | ABBV | https://www.nasdaq.com/articles/7-dividend-stocks-to-finance-your-golden-years | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Make hay while the sun shines. This old saying was certainly in full effect for the past decade when it came to the markets. But today, market forces we haven’t seen for a decade are making dividend stocks much more attractive again.
Imagine we were living ... | AbbVie (NYSE:ABBV) American Tower REIT (NYSE:AMT) Comcast Corp (NASDAQ:CMCSA) Caterpillar (NYSE:CAT) Morgan Stanley (NYSE:MS) Amgen (NASDAQ:AMGN) Blackstone (NYSE:BX) Dividend Stocks: AbbVie (ABBV) Source: Piotr Swat / Shutterstock.com With a $264 billion market cap, ABBV is well and truly a major pharmaceutical compan... | AbbVie (NYSE:ABBV) American Tower REIT (NYSE:AMT) Comcast Corp (NASDAQ:CMCSA) Caterpillar (NYSE:CAT) Morgan Stanley (NYSE:MS) Amgen (NASDAQ:AMGN) Blackstone (NYSE:BX) Dividend Stocks: AbbVie (ABBV) Source: Piotr Swat / Shutterstock.com With a $264 billion market cap, ABBV is well and truly a major pharmaceutical compan... | AbbVie (NYSE:ABBV) American Tower REIT (NYSE:AMT) Comcast Corp (NASDAQ:CMCSA) Caterpillar (NYSE:CAT) Morgan Stanley (NYSE:MS) Amgen (NASDAQ:AMGN) Blackstone (NYSE:BX) Dividend Stocks: AbbVie (ABBV) Source: Piotr Swat / Shutterstock.com With a $264 billion market cap, ABBV is well and truly a major pharmaceutical compan... | AbbVie (NYSE:ABBV) American Tower REIT (NYSE:AMT) Comcast Corp (NASDAQ:CMCSA) Caterpillar (NYSE:CAT) Morgan Stanley (NYSE:MS) Amgen (NASDAQ:AMGN) Blackstone (NYSE:BX) Dividend Stocks: AbbVie (ABBV) Source: Piotr Swat / Shutterstock.com With a $264 billion market cap, ABBV is well and truly a major pharmaceutical compan... |
23,555 | 2022-03-09 00:00:00 UTC | Genmab (GMAB), AbbVie Lymphoma Candidate Gets Orphan Drug Tag | ABBV | https://www.nasdaq.com/articles/genmab-gmab-abbvie-lymphoma-candidate-gets-orphan-drug-tag | null | null | Denmark-based biotech Genmab A/S GMAB received Orphan Drug designation for its antibody product candidate, epcoritamab, for treating follicular lymphoma (“FL”) from the FDA.
The orphan drug designation is granted by the FDA to a drug or biologic intended to treat a rare disease or condition, which generally includes a ... | Please note that Genmab is co-developing the candidate with AbbVie ABBV. Genmab and AbbVie inked an oncology collaboration in 2020 to jointly develop and market three of Genmab’s early-stage investigational bispecific antibody product candidates including epcoritamab. AbbVie and Genmab share commercial responsibilities... | Please note that Genmab is co-developing the candidate with AbbVie ABBV. Genmab and AbbVie inked an oncology collaboration in 2020 to jointly develop and market three of Genmab’s early-stage investigational bispecific antibody product candidates including epcoritamab. AbbVie and Genmab share commercial responsibilities... | Genmab and AbbVie inked an oncology collaboration in 2020 to jointly develop and market three of Genmab’s early-stage investigational bispecific antibody product candidates including epcoritamab. A phase I/II study — EPCORE — is evaluating a subcutaneous formulation of Genmab and AbbVie’s candidate in patients with rel... | AbbVie Inc. (ABBV): Free Stock Analysis Report Please note that Genmab is co-developing the candidate with AbbVie ABBV. Genmab and AbbVie inked an oncology collaboration in 2020 to jointly develop and market three of Genmab’s early-stage investigational bispecific antibody product candidates including epcoritamab. |
23,556 | 2022-03-09 00:00:00 UTC | Health Care Sector Update for 03/09/2022: AMYT, PFE, ABBV, IBB, XLV | ABBV | https://www.nasdaq.com/articles/health-care-sector-update-for-03-09-2022%3A-amyt-pfe-abbv-ibb-xlv | null | null | Health care stocks were climbing premarket Wednesday. The iShares Biotechnology ETF (IBB) and the Health Care SPDR (XLV) were recently up around 2%.
Amryt Pharma (AMYT) reported Q4 net earnings of $0.07 per diluted share, compared with a loss of $0.28 per share a year earlier. Three analysts polled by Capital IQ expect... | AbbVie (ABBV) was up more than 1% after saying it has granted Alvotech Holdings non-exclusive rights to market its Humira biosimilar product in the US, effective July 1, 2023, as part of a settlement agreement. The iShares Biotechnology ETF (IBB) and the Health Care SPDR (XLV) were recently up around 2%. Pfizer (PFE) s... | AbbVie (ABBV) was up more than 1% after saying it has granted Alvotech Holdings non-exclusive rights to market its Humira biosimilar product in the US, effective July 1, 2023, as part of a settlement agreement. Health care stocks were climbing premarket Wednesday. Amryt Pharma (AMYT) reported Q4 net earnings of $0.07 p... | AbbVie (ABBV) was up more than 1% after saying it has granted Alvotech Holdings non-exclusive rights to market its Humira biosimilar product in the US, effective July 1, 2023, as part of a settlement agreement. The iShares Biotechnology ETF (IBB) and the Health Care SPDR (XLV) were recently up around 2%. Amryt Pharma (... | AbbVie (ABBV) was up more than 1% after saying it has granted Alvotech Holdings non-exclusive rights to market its Humira biosimilar product in the US, effective July 1, 2023, as part of a settlement agreement. The iShares Biotechnology ETF (IBB) and the Health Care SPDR (XLV) were recently up around 2%. Three analysts... |
23,557 | 2022-03-09 00:00:00 UTC | What's in Store for These 3 Big Pharma Outperformers in 2022? | ABBV | https://www.nasdaq.com/articles/whats-in-store-for-these-3-big-pharma-outperformers-in-2022 | null | null | The recently ended fourth-quarter earnings season was a mixed bag for the drug and biotech sector. Most companies beat estimates for earnings while missing the same for sales or vice versa. However, some companies have not only been able to beat consensus estimates but also guide better than market expectations for 202... | Among AbbVie’s other immunology medicines, Skyrizi and Rinvoq demonstrated differentiated clinical profiles versus Humira and are already contributing meaningful revenues, including $4.6 billion in combined sales in 2021. Image Source: Zacks Investment Research However, we expect the drug and biotech sector to rebound ... | In 2022, AbbVie expects its immunology sales to grow in double digits, including U.S. Humira growth of 8%, Skyrizi global sales of $4.4 billion and Rinvoq global sales of $2.7 billion. Image Source: Zacks Investment Research However, we expect the drug and biotech sector to rebound once the overall market recovers due ... | Image Source: Zacks Investment Research However, we expect the drug and biotech sector to rebound once the overall market recovers due to its strong fundamentals, an expected pick-up in M&A activity, including possible mega-mergers and positive pipeline and regulatory updates Here we have highlighted three bigshot drug... | Image Source: Zacks Investment Research However, we expect the drug and biotech sector to rebound once the overall market recovers due to its strong fundamentals, an expected pick-up in M&A activity, including possible mega-mergers and positive pipeline and regulatory updates Here we have highlighted three bigshot drug... |
23,558 | 2022-03-09 00:00:00 UTC | 8 Strong Uptrend Stocks to Buy on the Next Dip | ABBV | https://www.nasdaq.com/articles/8-strong-uptrend-stocks-to-buy-on-the-next-dip | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Given the remarkable volatility we’ve seen this year, it’s a wonder there are any uptrend stocks left to find. As the saying goes, though, “There’s always a bull market somewhere.” It’s an observation that holds even in volatile 2022.
U.S. stocks topped ou... | Chevron (NYSE:CVX) AbbVie (NYSE:ABBV) Coca-Cola (NYSE:KO) Raytheon (NYSE:RTX) Lockheed Martin (NYSE:LMT) Freeport-McMoRan (NYSE:FCX) Bristol-Myers Squibb (NYSE:BMY) Alcoa (NYSE:AA) Uptrend Stocks to Watch: Chevron (CVX) Source: Jeff Whyte / Shutterstock.com Chevron has been an energy sector leader, and energy has been ... | Chevron (NYSE:CVX) AbbVie (NYSE:ABBV) Coca-Cola (NYSE:KO) Raytheon (NYSE:RTX) Lockheed Martin (NYSE:LMT) Freeport-McMoRan (NYSE:FCX) Bristol-Myers Squibb (NYSE:BMY) Alcoa (NYSE:AA) Uptrend Stocks to Watch: Chevron (CVX) Source: Jeff Whyte / Shutterstock.com Chevron has been an energy sector leader, and energy has been ... | Chevron (NYSE:CVX) AbbVie (NYSE:ABBV) Coca-Cola (NYSE:KO) Raytheon (NYSE:RTX) Lockheed Martin (NYSE:LMT) Freeport-McMoRan (NYSE:FCX) Bristol-Myers Squibb (NYSE:BMY) Alcoa (NYSE:AA) Uptrend Stocks to Watch: Chevron (CVX) Source: Jeff Whyte / Shutterstock.com Chevron has been an energy sector leader, and energy has been ... | Chevron (NYSE:CVX) AbbVie (NYSE:ABBV) Coca-Cola (NYSE:KO) Raytheon (NYSE:RTX) Lockheed Martin (NYSE:LMT) Freeport-McMoRan (NYSE:FCX) Bristol-Myers Squibb (NYSE:BMY) Alcoa (NYSE:AA) Uptrend Stocks to Watch: Chevron (CVX) Source: Jeff Whyte / Shutterstock.com Chevron has been an energy sector leader, and energy has been ... |
23,559 | 2022-03-08 00:00:00 UTC | AbbVie Resolves All U.S. HUMIRA Litigation With Alvotech | ABBV | https://www.nasdaq.com/articles/abbvie-resolves-all-u.s.-humira-litigation-with-alvotech | null | null | (RTTNews) - AbbVie (ABBV) said that it has resolved all U.S. HUMIRA (adalimumab) litigation with Alvotech.
As per the terms of the resolution, AbbVie will grant Alvotech a non-exclusive license to its HUMIRA-related patents in the United States, which will begin on July 1, 2023.
AbbVie will make no payments of any form... | (RTTNews) - AbbVie (ABBV) said that it has resolved all U.S. HUMIRA (adalimumab) litigation with Alvotech. As per the terms of the resolution, AbbVie will grant Alvotech a non-exclusive license to its HUMIRA-related patents in the United States, which will begin on July 1, 2023. AbbVie will make no payments of any form... | (RTTNews) - AbbVie (ABBV) said that it has resolved all U.S. HUMIRA (adalimumab) litigation with Alvotech. As per the terms of the resolution, AbbVie will grant Alvotech a non-exclusive license to its HUMIRA-related patents in the United States, which will begin on July 1, 2023. AbbVie will make no payments of any form... | AbbVie will make no payments of any form to Alvotech, and Alvotech will pay royalties to AbbVie for licensing its HUMIRA patents and acknowledges the validity and enforceability of the licensed patents. (RTTNews) - AbbVie (ABBV) said that it has resolved all U.S. HUMIRA (adalimumab) litigation with Alvotech. As per the... | (RTTNews) - AbbVie (ABBV) said that it has resolved all U.S. HUMIRA (adalimumab) litigation with Alvotech. As per the terms of the resolution, AbbVie will grant Alvotech a non-exclusive license to its HUMIRA-related patents in the United States, which will begin on July 1, 2023. AbbVie will make no payments of any form... |
23,560 | 2022-03-08 00:00:00 UTC | AbbVie (ABBV) Outperforms Industry This Year So Far: What Next? | ABBV | https://www.nasdaq.com/articles/abbvie-abbv-outperforms-industry-this-year-so-far%3A-what-next | null | null | AbbVie ABBV stock has risen 11.6% this year so far compared with a decrease of 3.1% for the industry.
Image Source: Zacks Investment Research
AbbVie has become one of the top-most pharma companies after it acquired Botox maker Allergan in a cash-and-stock deal for $63 billion in May 2020. The deal has transformed Abb... | Image Source: Zacks Investment Research AbbVie has become one of the top-most pharma companies after it acquired Botox maker Allergan in a cash-and-stock deal for $63 billion in May 2020. The deal has transformed AbbVie’s portfolio by lowering its dependence on Humira, its flagship product, which has already lost paten... | In 2022, AbbVie expects its immunology sales to grow in double digits, including U.S. Humira growth of 8%, Skyrizi global sales of $4.4 billion and Rinvoq global sales of $2.7 billion. Robust demand for Botox Cosmetic and Juvederm is boosting sales of AbbVie’s aesthetics franchise, helped by a strong recovery from the ... | In 2022, AbbVie expects its immunology sales to grow in double digits, including U.S. Humira growth of 8%, Skyrizi global sales of $4.4 billion and Rinvoq global sales of $2.7 billion. AbbVie expects combined sales of Skyrizi and Rinvoq to be more than $15 billion by 2025. In 2022, AbbVie expects the global aesthetics ... | In 2022, AbbVie expects its immunology sales to grow in double digits, including U.S. Humira growth of 8%, Skyrizi global sales of $4.4 billion and Rinvoq global sales of $2.7 billion. AbbVie ABBV stock has risen 11.6% this year so far compared with a decrease of 3.1% for the industry. Image Source: Zacks Investment Re... |
23,561 | 2022-03-08 00:00:00 UTC | Top Analyst Reports for Microsoft, Amazon & NVIDIA | ABBV | https://www.nasdaq.com/articles/top-analyst-reports-for-microsoft-amazon-nvidia | null | null | Tuesday, March 8, 2022
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Microsoft Corporation (MSFT), Amazon.com, Inc. (AMZN) and NVIDIA Corporation (NVDA). These research reports have been hand-picked fro... | (You can read the full research report on NVIDIA here >>>) Other noteworthy reports we are featuring today include AbbVie Inc. (ABBV), HSBC Holdings plc (HSBC) and Visa Inc. (V). Today's Must Read Adoption of Cloud & Office 365 Strength Aid Microsoft (MSFT) Prime Momentum & Growing AWS Adoption Benefit Amazon (AMZN) St... | Today's Must Read Adoption of Cloud & Office 365 Strength Aid Microsoft (MSFT) Prime Momentum & Growing AWS Adoption Benefit Amazon (AMZN) Strong GPU Adoption in Gaming, Datacenter Aids NVIDIA (NVDA) Featured Reports AbbVie's (ABBV) Pipeline & New Drugs Key to Long-Term Growth The Zacks analyst says that AbbVie (ABBV) ... | Today's Must Read Adoption of Cloud & Office 365 Strength Aid Microsoft (MSFT) Prime Momentum & Growing AWS Adoption Benefit Amazon (AMZN) Strong GPU Adoption in Gaming, Datacenter Aids NVIDIA (NVDA) Featured Reports AbbVie's (ABBV) Pipeline & New Drugs Key to Long-Term Growth The Zacks analyst says that AbbVie (ABBV) ... | Today's Must Read Adoption of Cloud & Office 365 Strength Aid Microsoft (MSFT) Prime Momentum & Growing AWS Adoption Benefit Amazon (AMZN) Strong GPU Adoption in Gaming, Datacenter Aids NVIDIA (NVDA) Featured Reports AbbVie's (ABBV) Pipeline & New Drugs Key to Long-Term Growth The Zacks analyst says that AbbVie (ABBV) ... |
23,562 | 2022-03-07 00:00:00 UTC | What's Next For Merck Stock After A 6% Fall In A Month? | ABBV | https://www.nasdaq.com/articles/whats-next-for-merck-stock-after-a-6-fall-in-a-month | null | null | The stock price of Merck (NYSE: MRK) has seen a fall of 6% over the last month, while it is down 1% year-to-date. This marks a better performance than the broader markets, with the S&P500 down 6% over the last month but down 10% so far this year. The decline in broader markets can be attributed to the geopolitical tens... | The decline in broader markets can be attributed to the geopolitical tensions with Russia and Ukraine and its impact on oil prices. On the positive side, Merck’s Q4 results (announced last month) were comfortably above the street estimates aided by its Covid-19 pill sales, along with continued market share gains for it... | Merck (MRK) Stock Return (Recent) Comparison With Peers Five-Day Return: LLY highest at 4.3%; PFE lowest at -3.7% Ten-Day Return: LLY highest at 6.3%; PFE lowest at -8.1% Twenty-One Days Return: BMY highest at 5.7%; PFE lowest at -15.8% may have moved, 2020 has created many pricing discontinuities which can offer attra... | Out of 201 instances in the last ten years that MRK stock saw a twenty-one-day fall of 6% or more, 136 of them resulted in MRK stock rising over the subsequent one-month period (twenty-one trading days). Merck (MRK) Stock Return (Recent) Comparison With Peers Five-Day Return: LLY highest at 4.3%; PFE lowest at -3.7% Te... | While MRK stock may see higher levels over the next month, seeing how its peers stack up is helpful. This pattern suggests a higher chance of a rise in MRK stock over the next five days, ten days, and one month. Total [2] MRK Return 0% 0% 30% S&P 500 Return -1% -10% 92% Trefis MS Portfolio Return 0% -11% 252% [1] Month... |
23,563 | 2022-03-06 00:00:00 UTC | You Could Make $48,840 in Annual Income by Buying These 10 Stocks | ABBV | https://www.nasdaq.com/articles/you-could-make-%2448840-in-annual-income-by-buying-these-10-stocks | null | null | Let first give you the cold, hard truth. It takes money to make money. You're not going to magically receive a significant income each year without having a hefty amount of cash to invest.
But the good news is that many Americans who have consistently saved and invested throughout their careers can retire with $1 milli... | And even with its top-selling drug, Humira, facing loss of U.S. exclusivity next year, AbbVie should be in great shape to keep growing its dividend. Devon Energy ~8% $8,000 Enterprise Products Partners 7.55% $7,550 Chevron 3.68% $3,680 Brookfield Renewable Corporation 3.41% $3,410 AbbVie 3.77% $3,770 Pfizer 3.35% $3,35... | Devon Energy ~8% $8,000 Enterprise Products Partners 7.55% $7,550 Chevron 3.68% $3,680 Brookfield Renewable Corporation 3.41% $3,410 AbbVie 3.77% $3,770 Pfizer 3.35% $3,350 Easterly Government Properties 5.05% $5,050 Medical Properties Trust 5.72% $5,720 Brookfield Infrastructure Partners 3.58% $3,580 Verizon Communica... | Devon Energy ~8% $8,000 Enterprise Products Partners 7.55% $7,550 Chevron 3.68% $3,680 Brookfield Renewable Corporation 3.41% $3,410 AbbVie 3.77% $3,770 Pfizer 3.35% $3,350 Easterly Government Properties 5.05% $5,050 Medical Properties Trust 5.72% $5,720 Brookfield Infrastructure Partners 3.58% $3,580 Verizon Communica... | Devon Energy ~8% $8,000 Enterprise Products Partners 7.55% $7,550 Chevron 3.68% $3,680 Brookfield Renewable Corporation 3.41% $3,410 AbbVie 3.77% $3,770 Pfizer 3.35% $3,350 Easterly Government Properties 5.05% $5,050 Medical Properties Trust 5.72% $5,720 Brookfield Infrastructure Partners 3.58% $3,580 Verizon Communica... |
23,564 | 2022-03-05 00:00:00 UTC | 4 Defensive Stocks To Watch As Russia-Ukraine War Intensifies | ABBV | https://www.nasdaq.com/articles/4-defensive-stocks-to-watch-as-russia-ukraine-war-intensifies | null | null | Do You Have These Defensive Stocks On Your March 2022 Watchlist?
Among the main concerns on investors’ minds now would be the ongoing war in Ukraine and upcoming interest rate hikes. With these two daunting factors to consider moving forward, defensive stocks could be in focus in the stock market now. Overall, markets ... | Now, as part of AbbVie, the program is well-positioned to move into later stages of clinical development.” Given the potential of its lead molecule, is ABBV stock a buy? Defensive Stocks To Watch Right Now Costco Wholesale Corporation (NASDAQ: COST) Algonquin Power & Utilities Corporation (NYSE: AQN) AbbVie Inc. (NYSE:... | Defensive Stocks To Watch Right Now Costco Wholesale Corporation (NASDAQ: COST) Algonquin Power & Utilities Corporation (NYSE: AQN) AbbVie Inc. (NYSE: ABBV) Energizer Holdings Inc. (NYSE: ENR) Costco Wholesale Costco would be a notable name in the defensive space to consider now. AbbVie Following that is leading biopha... | Defensive Stocks To Watch Right Now Costco Wholesale Corporation (NASDAQ: COST) Algonquin Power & Utilities Corporation (NYSE: AQN) AbbVie Inc. (NYSE: ABBV) Energizer Holdings Inc. (NYSE: ENR) Costco Wholesale Costco would be a notable name in the defensive space to consider now. AbbVie Following that is leading biopha... | Defensive Stocks To Watch Right Now Costco Wholesale Corporation (NASDAQ: COST) Algonquin Power & Utilities Corporation (NYSE: AQN) AbbVie Inc. (NYSE: ABBV) Energizer Holdings Inc. (NYSE: ENR) Costco Wholesale Costco would be a notable name in the defensive space to consider now. AbbVie Following that is leading biopha... |
23,565 | 2022-03-05 00:00:00 UTC | 1 Healthcare Stock That Could Fly Higher After a Strong Q4 | ABBV | https://www.nasdaq.com/articles/1-healthcare-stock-that-could-fly-higher-after-a-strong-q4 | null | null | The pharmaceutical business can be challenging for companies and investors as money is poured into developing drugs that may or may not achieve U.S. Food and Drug Administration (FDA) or international approval to market and sell.
Innoviva (NASDAQ: INVA) approaches investing in pharmaceuticals differently. It doesn't ma... | Vertex Pharmaceuticals owns about a 97% market share, and AbbVie has active phase 2 clinical trials for its own treatment, so moving in on these rivals will not be easy. Innoviva's portfolio of royalties is anchored by a partnership with GlaxoSmithKline along with a growing stable of healthcare investments in companies... | Vertex Pharmaceuticals owns about a 97% market share, and AbbVie has active phase 2 clinical trials for its own treatment, so moving in on these rivals will not be easy. The partnership with GSK is the primary revenue generator for Innoviva and is based on a portfolio of Ellipta inhalers offered globally across four br... | Vertex Pharmaceuticals owns about a 97% market share, and AbbVie has active phase 2 clinical trials for its own treatment, so moving in on these rivals will not be easy. Total respiratory sales were up 20% in Q4 for GSK, helped along by the increased sales of Trelegy -- a good sign for future royalties to Innoviva if s... | Vertex Pharmaceuticals owns about a 97% market share, and AbbVie has active phase 2 clinical trials for its own treatment, so moving in on these rivals will not be easy. As part of the initial partnership, GSK invested in Innoviva as well, owning approximately one-third of the company's outstanding shares. Total respir... |
23,566 | 2022-03-04 00:00:00 UTC | AbbVie (ABBV) Up 6.9% Since Last Earnings Report: Can It Continue? | ABBV | https://www.nasdaq.com/articles/abbvie-abbv-up-6.9-since-last-earnings-report%3A-can-it-continue | null | null | It has been about a month since the last earnings report for AbbVie (ABBV). Shares have added about 6.9% in that time frame, outperforming the S&P 500.
Will the recent positive trend continue leading up to its next earnings release, or is AbbVie due for a pullback? Before we dive into how investors and analysts have re... | AbbVie’s aesthetics portfolio sales were up 23.3% and 22.8% on a reported and operational basis, respectively, to $1.41 billion on the back of robust demand for Botox Cosmetic and Juvederm helped by a strong recovery from the pandemic. It has been about a month since the last earnings report for AbbVie (ABBV). Will the... | AbbVie’s oncology/hematology (including Imbruvica and Venclexta) sales rose 4.6% (4.7% on an operational basis) to $1.87 billion in the quarter, driven by the strong growth of Venclexta sales, partially offset by lower U.S. sales of Imbruvica. AbbVie expects global neuroscience sales of $6.9 billion, including Botox Th... | In 2022, AbbVie expects its immunology sales to grow in double digits, including U.S. Humira growth of 8%, international Humira revenues of $2.6 billion at current exchange rates, Skyrizi global sales of $4.4 billion and Rinvoq global sales of $2.7 billion. AbbVie expects global neuroscience sales of $6.9 billion, incl... | AbbVie expects global neuroscience sales of $6.9 billion, including Botox Therapeutic sales of $2.7 billion, Vraylar sales of $2.2 billion, Ubrelvy sales of $800 million and Qulipta sales of $200 million. It has been about a month since the last earnings report for AbbVie (ABBV). Will the recent positive trend continue... |
23,567 | 2022-03-04 00:00:00 UTC | 1 Stock Warren Buffett Is Selling That Income Investors Should Consider Buying | ABBV | https://www.nasdaq.com/articles/1-stock-warren-buffett-is-selling-that-income-investors-should-consider-buying | null | null | Warren Buffett appears to be selling more stocks than he's buying these days. Berkshire Hathaway (NYSE: BRK.A) (NYSE: BRK.B) recently revealed its equity holdings for the fourth quarter of 2021 in a regulatory filing. Buffett and his investment managers sold 10 stocks while buying seven stocks.
The legendary investor u... | A lot to like Buffett has steadily trimmed Berkshire's stake in big-drugmaker AbbVie (NYSE: ABBV) for several quarters. More importantly, AbbVie's broader product lineup should enable the company to quickly return to solid growth. However, there's a lot to like about AbbVie for income investors. | See the 10 stocks *Stock Advisor returns as of January 20, 2022 Keith Speights owns AbbVie and Berkshire Hathaway (B shares). A lot to like Buffett has steadily trimmed Berkshire's stake in big-drugmaker AbbVie (NYSE: ABBV) for several quarters. However, there's a lot to like about AbbVie for income investors. | * They just revealed what they believe are the ten best stocks for investors to buy right now... and AbbVie wasn't one of them! See the 10 stocks *Stock Advisor returns as of January 20, 2022 Keith Speights owns AbbVie and Berkshire Hathaway (B shares). A lot to like Buffett has steadily trimmed Berkshire's stake in bi... | * They just revealed what they believe are the ten best stocks for investors to buy right now... and AbbVie wasn't one of them! See the 10 stocks *Stock Advisor returns as of January 20, 2022 Keith Speights owns AbbVie and Berkshire Hathaway (B shares). A lot to like Buffett has steadily trimmed Berkshire's stake in bi... |
23,568 | 2022-03-03 00:00:00 UTC | Is This Dividend King a Buy for 2022 and Beyond? | ABBV | https://www.nasdaq.com/articles/is-this-dividend-king-a-buy-for-2022-and-beyond | null | null | High inflation rates, looming interest rate hikes, and most recently Russia's invasion of Ukraine have all led to a return of market volatility in 2022. For context, the S&P 500 has fallen 9% year to date.
One company that has nevertheless managed to do well lately is pharma stock AbbVie (NYSE: ABBV), whose shares are ... | One company that has nevertheless managed to do well lately is pharma stock AbbVie (NYSE: ABBV), whose shares are up 11% year to date. This raises the following questions: Has AbbVie's rally been overdone? Let's dive into AbbVie's fundamentals and valuation to address these questions. | AbbVie's revenue and earnings keep moving higher AbbVie delivered healthy revenue and earnings growth in 2021, reporting $56.1 billion in sales last year, which represents a 22.6% growth rate against 2020. Thanks to the company's existing drug portfolio and its pipeline of several dozen indications, analysts expect Abb... | AbbVie's revenue and earnings keep moving higher AbbVie delivered healthy revenue and earnings growth in 2021, reporting $56.1 billion in sales last year, which represents a 22.6% growth rate against 2020. And with AbbVie expecting an FDA approval this month for Rinvoq to treat ulcerative colitis and an FDA approval fo... | One company that has nevertheless managed to do well lately is pharma stock AbbVie (NYSE: ABBV), whose shares are up 11% year to date. This raises the following questions: Has AbbVie's rally been overdone? Let's dive into AbbVie's fundamentals and valuation to address these questions. |
23,569 | 2022-03-03 00:00:00 UTC | Viatris Just Snagged a Major FDA Approval | ABBV | https://www.nasdaq.com/articles/viatris-just-snagged-a-major-fda-approval | null | null | In early February, the U.S. Food and Drug Administration (FDA) gave the nod to Viatris' (NASDAQ: VTRS) Restasis, a generic version of AbbVie's (NYSE: ABBV) dry eye disease eyedrop treatment.
Since Viatris launched the drug in the U.S. immediately after the FDA approval, let's dig into what it could mean for patients an... | In early February, the U.S. Food and Drug Administration (FDA) gave the nod to Viatris' (NASDAQ: VTRS) Restasis, a generic version of AbbVie's (NYSE: ABBV) dry eye disease eyedrop treatment. For example, AbbVie's Restasis was approved by the FDA in 2003, which made it the first treatment option available to patients wi... | In early February, the U.S. Food and Drug Administration (FDA) gave the nod to Viatris' (NASDAQ: VTRS) Restasis, a generic version of AbbVie's (NYSE: ABBV) dry eye disease eyedrop treatment. Until the FDA approved Viatris' generic version of Restasis, AbbVie's branded Restasis came with an annual list price of $7,000. ... | In early February, the U.S. Food and Drug Administration (FDA) gave the nod to Viatris' (NASDAQ: VTRS) Restasis, a generic version of AbbVie's (NYSE: ABBV) dry eye disease eyedrop treatment. My best guess is that Viatris' generic drug will be able to siphon off 25% of Restasis' $1.23 billion U.S. sales volumes, which c... | Since Viatris' generic drug will likely be about 40% cheaper, this would be a $180 million yearly sales boost for Viatris at AbbVie's expense. In early February, the U.S. Food and Drug Administration (FDA) gave the nod to Viatris' (NASDAQ: VTRS) Restasis, a generic version of AbbVie's (NYSE: ABBV) dry eye disease eyedr... |
23,570 | 2022-03-02 00:00:00 UTC | 2 Fantastic Dividend Stocks for Retirees | ABBV | https://www.nasdaq.com/articles/2-fantastic-dividend-stocks-for-retirees | null | null | Many retirees face the challenge of how to bring in regular income beyond their Social Security benefits. One way to make sure the bill are paid (or in some cases, the beach house mortgage is covered) is to invest in companies that pay dividends.
AbbVie (NYSE: ABBV) and Kimberly-Clark (NYSE: KMB) are two income stocks ... | Thanks to a strong pipeline, a strategic acquisition, healthy dividends, and a management team optimizing operating margin, AbbVie could provide retirees with an investment opportunity to pull in the additional income they seek throughout their golden years. AbbVie (NYSE: ABBV) and Kimberly-Clark (NYSE: KMB) are two in... | Though price appreciation trails AbbVie, Kimberly-Clark pays an annual dividend of $4.64 at a yield of 3.52%, compared to a 2.25% average for consumer goods stocks in the S&P. If I had to choose between one or the other right now, I'd go with AbbVie, based on its growth trajectory, stock price history, and higher annua... | AbbVie and Kimberly Clark have been increasing dividends for 50 consecutive years, earning them the status of Dividend Kings. Though price appreciation trails AbbVie, Kimberly-Clark pays an annual dividend of $4.64 at a yield of 3.52%, compared to a 2.25% average for consumer goods stocks in the S&P. If I had to choose... | On average, AbbVie has increased its dividend by 11% per year going back to 2015. AbbVie (NYSE: ABBV) and Kimberly-Clark (NYSE: KMB) are two income stocks that investors nearing retirement may want to consider buying in the pursuit of stress-free Golden Years. AbbVie and Kimberly Clark have been increasing dividends fo... |
23,571 | 2022-03-02 00:00:00 UTC | Consumer Spending, E-Commerce, and the Business of Lodging | ABBV | https://www.nasdaq.com/articles/consumer-spending-e-commerce-and-the-business-of-lodging | null | null | In this week's episode of Motley Fool Money, Motley Fool analyst Olivia Zitkus and Motley Fool contributor Keith Speights, along with host Chris Hill, discuss a new wave of biosimilar drugs and the challenges (and opportunities for investors) that they present. Also, Motley Fool analyst Bill Mann discusses:
Retail sale... | In addition to its agreement with Amgen, AbbVie has at least eight other Humira biosimilar settlements with companies like Boehringer Ingelheim, Viatris, Samsung Bioepis, Mylan, and Novartis. The bottom line is that AbbVie will definitely feel some pain from biosimilar competition in the US market for Humira, but the c... | AbbVie's biologic Humira, a medicine approved to treat symptoms of various inflammatory conditions is the top drug in the industry by sales. In addition to its agreement with Amgen, AbbVie has at least eight other Humira biosimilar settlements with companies like Boehringer Ingelheim, Viatris, Samsung Bioepis, Mylan, a... | AbbVie's biologic Humira, a medicine approved to treat symptoms of various inflammatory conditions is the top drug in the industry by sales. In addition to its agreement with Amgen, AbbVie has at least eight other Humira biosimilar settlements with companies like Boehringer Ingelheim, Viatris, Samsung Bioepis, Mylan, a... | AbbVie's biologic Humira, a medicine approved to treat symptoms of various inflammatory conditions is the top drug in the industry by sales. In addition to its agreement with Amgen, AbbVie has at least eight other Humira biosimilar settlements with companies like Boehringer Ingelheim, Viatris, Samsung Bioepis, Mylan, a... |
23,572 | 2022-03-02 00:00:00 UTC | Harpoon Therapeutics: HPN217 Receives FDA Fast Track Designation | ABBV | https://www.nasdaq.com/articles/harpoon-therapeutics%3A-hpn217-receives-fda-fast-track-designation | null | null | (RTTNews) - Harpoon Therapeutics, Inc. (HARP) said FDA has granted Fast Track designation to HPN217, a BCMA-targeting TriTAC, for the treatment of patients with relapsed, refractory multiple myeloma who have received at least four lines of therapy.
Julie Eastland, President and CEO, Harpoon Therapeutics, said: "We are ... | (RTTNews) - Harpoon Therapeutics, Inc. (HARP) said FDA has granted Fast Track designation to HPN217, a BCMA-targeting TriTAC, for the treatment of patients with relapsed, refractory multiple myeloma who have received at least four lines of therapy. Julie Eastland, President and CEO, Harpoon Therapeutics, said: "We are ... | (RTTNews) - Harpoon Therapeutics, Inc. (HARP) said FDA has granted Fast Track designation to HPN217, a BCMA-targeting TriTAC, for the treatment of patients with relapsed, refractory multiple myeloma who have received at least four lines of therapy. Julie Eastland, President and CEO, Harpoon Therapeutics, said: "We are ... | (RTTNews) - Harpoon Therapeutics, Inc. (HARP) said FDA has granted Fast Track designation to HPN217, a BCMA-targeting TriTAC, for the treatment of patients with relapsed, refractory multiple myeloma who have received at least four lines of therapy. Julie Eastland, President and CEO, Harpoon Therapeutics, said: "We are ... | (RTTNews) - Harpoon Therapeutics, Inc. (HARP) said FDA has granted Fast Track designation to HPN217, a BCMA-targeting TriTAC, for the treatment of patients with relapsed, refractory multiple myeloma who have received at least four lines of therapy. Julie Eastland, President and CEO, Harpoon Therapeutics, said: "We are ... |
23,573 | 2022-03-02 00:00:00 UTC | Has the Market Correction Made AbbVie Stock Cheap? | ABBV | https://www.nasdaq.com/articles/has-the-market-correction-made-abbvie-stock-cheap | null | null | With the stock market down about 8% so far this year -- and briefly entering correction territory last week -- investors are on the lookout for shares of quality companies that have dropped into bargain territory. AbbVie's (NYSE: ABBV) stock, however, has been moving up rather than down so far in 2022. Is it a buy?
Bef... | AbbVie's (NYSE: ABBV) stock, however, has been moving up rather than down so far in 2022. Before approaching the question of AbbVie's valuation directly, let's look at where the company plans to go over the next few years, as well as its recent performance. A look at the numbers For AbbVie, business is proceeding as pl... | ABBV Revenue (Quarterly) data by YCharts. AbbVie's (NYSE: ABBV) stock, however, has been moving up rather than down so far in 2022. Before approaching the question of AbbVie's valuation directly, let's look at where the company plans to go over the next few years, as well as its recent performance. | The first thing to recognize about its valuation is that AbbVie's shares have gained 9% so far this year while the broader stock market has fallen by 8%. AbbVie's (NYSE: ABBV) stock, however, has been moving up rather than down so far in 2022. Before approaching the question of AbbVie's valuation directly, let's look a... | So AbbVie's shares do look slightly undervalued compared to others in the industry, though that seems to have nothing to do with the market correction. AbbVie's (NYSE: ABBV) stock, however, has been moving up rather than down so far in 2022. Before approaching the question of AbbVie's valuation directly, let's look at ... |
23,574 | 2022-03-01 00:00:00 UTC | U.S. lawmakers seek answers on 'troubling' drug price increases | ABBV | https://www.nasdaq.com/articles/u.s.-lawmakers-seek-answers-on-troubling-drug-price-increases | null | null | By Diane Bartz
WASHINGTON, March 1 (Reuters) - Senators Elizabeth Warren and Amy Klobuchar and 11 other U.S. lawmakers pressed the president of the biggest pharmaceutical industry trade group Tuesday about what they said were "troubling price increases for brand name drugs" in January.
A letter to Stephen Ubl, presiden... | Other drugs cited included AbbVie's ABBV.N big-selling rheumatoid arthritis treatment Humira Pen and leukemia drug Imbruvica, which saw their prices go up 7.4%. By Diane Bartz WASHINGTON, March 1 (Reuters) - Senators Elizabeth Warren and Amy Klobuchar and 11 other U.S. lawmakers pressed the president of the biggest pha... | Other drugs cited included AbbVie's ABBV.N big-selling rheumatoid arthritis treatment Humira Pen and leukemia drug Imbruvica, which saw their prices go up 7.4%. Schondelmeyer's study found that drugmakers increased prices for 72% of the 100 top-selling drugs in early 2022, with 26% of brand name drugs showing higher pr... | Other drugs cited included AbbVie's ABBV.N big-selling rheumatoid arthritis treatment Humira Pen and leukemia drug Imbruvica, which saw their prices go up 7.4%. By Diane Bartz WASHINGTON, March 1 (Reuters) - Senators Elizabeth Warren and Amy Klobuchar and 11 other U.S. lawmakers pressed the president of the biggest pha... | Other drugs cited included AbbVie's ABBV.N big-selling rheumatoid arthritis treatment Humira Pen and leukemia drug Imbruvica, which saw their prices go up 7.4%. By Diane Bartz WASHINGTON, March 1 (Reuters) - Senators Elizabeth Warren and Amy Klobuchar and 11 other U.S. lawmakers pressed the president of the biggest pha... |
23,575 | 2022-03-01 00:00:00 UTC | Warren, 12 other U.S. lawmakers press drugs lobby group on price increases | ABBV | https://www.nasdaq.com/articles/warren-12-other-u.s.-lawmakers-press-drugs-lobby-group-on-price-increases | null | null | By Diane Bartz
WASHINGTON, March 1 (Reuters) - Senators Elizabeth Warren and Amy Klobuchar and 11 other U.S. lawmakers pressed the president of the biggest pharmaceutical industry trade group on Tuesday about what they said were "troubling price increases for brand name drugs" in January.
A letter to Stephen Ubl, presi... | Other drugs cited included AbbVie's ABBV.N big-selling rheumatoid arthritis treatment Humira Pen and leukemia drug Imbruvica, which saw their prices go up 7.4%. By Diane Bartz WASHINGTON, March 1 (Reuters) - Senators Elizabeth Warren and Amy Klobuchar and 11 other U.S. lawmakers pressed the president of the biggest pha... | Other drugs cited included AbbVie's ABBV.N big-selling rheumatoid arthritis treatment Humira Pen and leukemia drug Imbruvica, which saw their prices go up 7.4%. Schondelmeyer's study found that drugmakers increased prices for 72% of the 100 top-selling drugs in early 2022, with 26% of brand name drugs showing higher pr... | Other drugs cited included AbbVie's ABBV.N big-selling rheumatoid arthritis treatment Humira Pen and leukemia drug Imbruvica, which saw their prices go up 7.4%. Schondelmeyer's study found that drugmakers increased prices for 72% of the 100 top-selling drugs in early 2022, with 26% of brand name drugs showing higher pr... | Other drugs cited included AbbVie's ABBV.N big-selling rheumatoid arthritis treatment Humira Pen and leukemia drug Imbruvica, which saw their prices go up 7.4%. The lawmakers, who included Representative Katie Porter, cited two studies: one by Dr. Stephen Schondelmeyer of the University of Minnesota and another by the ... |
23,576 | 2022-02-28 00:00:00 UTC | Reata's (RETA) Q4 Earnings Miss Mark, Revenues Decline Y/Y | ABBV | https://www.nasdaq.com/articles/reatas-reta-q4-earnings-miss-mark-revenues-decline-y-y | null | null | Reata Pharmaceuticals, Inc. RETA reported fourth-quarter 2021 loss of $2.35 per share, wider than the Zacks Consensus Estimate of a loss of $2.31.
However, the above loss included stock-based compensation and a non-cash interest expense. Adjusted loss for the quarter was $1.59 per share, also wider than the loss of $1.... | Reata had reacquired the development, manufacturing and commercialization rights for omaveloxolone and bardoxolone from AbbVie ABBV in 2019. The company also reacquired ex-U.S. rights to bardoxolone, omaveloxolone and its proprietary Nrf2 product platform from AbbVie during the same time. With this move, Reata is likel... | Reata had reacquired the development, manufacturing and commercialization rights for omaveloxolone and bardoxolone from AbbVie ABBV in 2019. The company also reacquired ex-U.S. rights to bardoxolone, omaveloxolone and its proprietary Nrf2 product platform from AbbVie during the same time. With this move, Reata is likel... | Reata had reacquired the development, manufacturing and commercialization rights for omaveloxolone and bardoxolone from AbbVie ABBV in 2019. The company also reacquired ex-U.S. rights to bardoxolone, omaveloxolone and its proprietary Nrf2 product platform from AbbVie during the same time. With this move, Reata is likel... | Reata had reacquired the development, manufacturing and commercialization rights for omaveloxolone and bardoxolone from AbbVie ABBV in 2019. The company also reacquired ex-U.S. rights to bardoxolone, omaveloxolone and its proprietary Nrf2 product platform from AbbVie during the same time. With this move, Reata is likel... |
23,577 | 2022-02-28 00:00:00 UTC | The 2 Best ETFs for Dividends | ABBV | https://www.nasdaq.com/articles/the-2-best-etfs-for-dividends | null | null | During a market like we have experienced over the past few months when the major benchmarks are posting negative year-to-date returns, dividend income becomes even more important for many investors. That extra income can either be reinvested back in stocks or an exchange-traded fund, at a cheaper price if the investmen... | The three largest holdings currently are Organon, AbbVie, and Valero Energy. During a market like we have experienced over the past few months when the major benchmarks are posting negative year-to-date returns, dividend income becomes even more important for many investors. Because it is focused on dividends, it inclu... | The three largest holdings currently are Organon, AbbVie, and Valero Energy. Two of the best ETFs on the market right now for dividend income are the SPDR Portfolio S&P 500 High Dividend ETF (NYSEMKT: SPYD) and the Invesco S&P Ultra Dividend Revenue ETF (NYSEMKT: RDIV). SPDR Portfolio S&P 500 High Dividend ETF The SPDR... | The three largest holdings currently are Organon, AbbVie, and Valero Energy. Two of the best ETFs on the market right now for dividend income are the SPDR Portfolio S&P 500 High Dividend ETF (NYSEMKT: SPYD) and the Invesco S&P Ultra Dividend Revenue ETF (NYSEMKT: RDIV). SPDR Portfolio S&P 500 High Dividend ETF The SPDR... | The three largest holdings currently are Organon, AbbVie, and Valero Energy. Many investors, particularly those in retirement, like to have that extra dividend income. It also includes a lot of value stocks, which have been outperforming growth over the past year. |
23,578 | 2022-02-27 00:00:00 UTC | Investing in Pharma Stocks? Avoid Doing These 3 Things | ABBV | https://www.nasdaq.com/articles/investing-in-pharma-stocks-avoid-doing-these-3-things | null | null | Pharmaceutical stocks can be great tools for building wealth, provided that you understand how and why to use them -- and how not to. Like all investments, it's entirely possible to get burned by pharma stocks, so you'll want to minimize the risks.
To help you on your journey, here are three of the biggest mistakes tha... | For example, one of the biggest questions for investors in AbbVie (NYSE: ABBV) is whether it'll be able to successfully navigate falling revenue from its blockbuster drug Humira once its exclusivity protections expire next year. If you see that the price-to-earnings multiple of AbbVie is around half that of its similar... | For example, one of the biggest questions for investors in AbbVie (NYSE: ABBV) is whether it'll be able to successfully navigate falling revenue from its blockbuster drug Humira once its exclusivity protections expire next year. If you see that the price-to-earnings multiple of AbbVie is around half that of its similar... | For example, one of the biggest questions for investors in AbbVie (NYSE: ABBV) is whether it'll be able to successfully navigate falling revenue from its blockbuster drug Humira once its exclusivity protections expire next year. If you see that the price-to-earnings multiple of AbbVie is around half that of its similar... | For example, one of the biggest questions for investors in AbbVie (NYSE: ABBV) is whether it'll be able to successfully navigate falling revenue from its blockbuster drug Humira once its exclusivity protections expire next year. If you see that the price-to-earnings multiple of AbbVie is around half that of its similar... |
23,579 | 2022-02-27 00:00:00 UTC | If You Invested $25,000 in AbbVie In 2013, This Is How Much You Would Have Today | ABBV | https://www.nasdaq.com/articles/if-you-invested-%2425000-in-abbvie-in-2013-this-is-how-much-you-would-have-today | null | null | AbbVie (NYSE: ABBV) is one of the top healthcare companies in the world, with a market cap of $256 billion. That's a higher valuation than Abbott Laboratories' $209 billion which AbbVie spun off from in 2013.
The stock has been a major performer for shareholders. But just how much would you have made if you'd invested ... | There's considerable value here from an investor's standpoint, as AbbVie can be a great source of recurring income with its juicy dividend yield and the business is well-positioned as doctors and hospitals resume their usual operations. AbbVie (NYSE: ABBV) is one of the top healthcare companies in the world, with a mar... | That's a higher valuation than Abbott Laboratories' $209 billion which AbbVie spun off from in 2013. Today, AbbVie's stock trades at a forward price-to-earnings multiple of 10, which is still relatively modest when compared to other notable healthcare companies, including Abbott Laboratories and Eli Lilly, which trade ... | Today, AbbVie's stock trades at a forward price-to-earnings multiple of 10, which is still relatively modest when compared to other notable healthcare companies, including Abbott Laboratories and Eli Lilly, which trade at 24 and 28 times their future earnings, respectively. 10 stocks we like better than AbbVie When our... | AbbVie (NYSE: ABBV) is one of the top healthcare companies in the world, with a market cap of $256 billion. That's a higher valuation than Abbott Laboratories' $209 billion which AbbVie spun off from in 2013. But just how much would you have made if you'd invested $25,000 in AbbVie when it first began trading? |
23,580 | 2022-02-27 00:00:00 UTC | These 5 Stocks Will Make Me More Than $3,000 in Passive Income This Year | ABBV | https://www.nasdaq.com/articles/these-5-stocks-will-make-me-more-than-%243000-in-passive-income-this-year | null | null | Easy money. It might seem like an elusive dream. However, investors actually have plenty of opportunities to make money without expending a lot of effort.
Dividend stocks especially stand out as an easy way to generate recurring income. And you don't have to give up on opportunities for growth with some dividend stocks... | AbbVie I own 117 shares of AbbVie (NYSE: ABBV). That means that my stake in AbbVie should make me a little over $634 in income in 2022. Am I worried that AbbVie's top-selling drug, Humira, faces the loss of exclusivity in the U.S. next year? | See the 10 stocks *Stock Advisor returns as of January 20, 2022 Keith Speights owns AbbVie, Brookfield Infrastructure Corporation, Brookfield Infrastructure Partners, Devon Energy, Innovative Industrial Properties, and Pfizer. AbbVie I own 117 shares of AbbVie (NYSE: ABBV). That means that my stake in AbbVie should mak... | See the 10 stocks *Stock Advisor returns as of January 20, 2022 Keith Speights owns AbbVie, Brookfield Infrastructure Corporation, Brookfield Infrastructure Partners, Devon Energy, Innovative Industrial Properties, and Pfizer. AbbVie I own 117 shares of AbbVie (NYSE: ABBV). That means that my stake in AbbVie should mak... | See the 10 stocks *Stock Advisor returns as of January 20, 2022 Keith Speights owns AbbVie, Brookfield Infrastructure Corporation, Brookfield Infrastructure Partners, Devon Energy, Innovative Industrial Properties, and Pfizer. AbbVie I own 117 shares of AbbVie (NYSE: ABBV). That means that my stake in AbbVie should mak... |
23,581 | 2022-02-26 00:00:00 UTC | 3 Pharma Stocks That Retired Investors Should Love | ABBV | https://www.nasdaq.com/articles/3-pharma-stocks-that-retired-investors-should-love | null | null | I loathe broccoli. But my family loves it. Different people have different preferences when it comes to food. It's a similar story with investing. Some stocks that appeal to younger investors won't appeal to retired investors -- and vice versa.
We asked three Motley Fool contributors to weigh in on pharmaceutical stock... | Here's why they picked AbbVie (NYSE: ABBV), Gilead Sciences (NASDAQ: GILD), and GlaxoSmithKline (NYSE: GSK). Checking off all the boxes Keith Speights (AbbVie): What do retired investors want from a stock? I think that AbbVie checks off all these boxes. | Here's why they picked AbbVie (NYSE: ABBV), Gilead Sciences (NASDAQ: GILD), and GlaxoSmithKline (NYSE: GSK). Checking off all the boxes Keith Speights (AbbVie): What do retired investors want from a stock? I think that AbbVie checks off all these boxes. | Here's why they picked AbbVie (NYSE: ABBV), Gilead Sciences (NASDAQ: GILD), and GlaxoSmithKline (NYSE: GSK). Checking off all the boxes Keith Speights (AbbVie): What do retired investors want from a stock? I think that AbbVie checks off all these boxes. | Some might wonder how strong AbbVie's business is now, though. Here's why they picked AbbVie (NYSE: ABBV), Gilead Sciences (NASDAQ: GILD), and GlaxoSmithKline (NYSE: GSK). Checking off all the boxes Keith Speights (AbbVie): What do retired investors want from a stock? |
23,582 | 2022-02-25 00:00:00 UTC | Noteworthy Friday Option Activity: MMM, CI, ABBV | ABBV | https://www.nasdaq.com/articles/noteworthy-friday-option-activity%3A-mmm-ci-abbv | null | null | Looking at options trading activity among components of the S&P 500 index, there is noteworthy activity today in 3M Co (Symbol: MMM), where a total volume of 30,918 contracts has been traded thus far today, a contract volume which is representative of approximately 3.1 million underlying shares (given that every 1 cont... | Particularly high volume was seen for the $145 strike call option expiring March 18, 2022, with 8,838 contracts trading so far today, representing approximately 883,800 underlying shares of ABBV. Below is a chart showing CI's trailing twelve month trading history, with the $240 strike highlighted in orange: And AbbVie ... | Below is a chart showing CI's trailing twelve month trading history, with the $240 strike highlighted in orange: And AbbVie Inc (Symbol: ABBV) options are showing a volume of 54,873 contracts thus far today. That number of contracts represents approximately 5.5 million underlying shares, working out to a sizeable 63.2%... | Below is a chart showing CI's trailing twelve month trading history, with the $240 strike highlighted in orange: And AbbVie Inc (Symbol: ABBV) options are showing a volume of 54,873 contracts thus far today. That number of contracts represents approximately 5.5 million underlying shares, working out to a sizeable 63.2%... | Below is a chart showing CI's trailing twelve month trading history, with the $240 strike highlighted in orange: And AbbVie Inc (Symbol: ABBV) options are showing a volume of 54,873 contracts thus far today. That number of contracts represents approximately 5.5 million underlying shares, working out to a sizeable 63.2%... |
23,583 | 2022-02-24 00:00:00 UTC | ABBV: Phase 3 Study Confirms Upadacitinib Improved Clinical & Endoscopic Outcomes In Crohn's Disease | ABBV | https://www.nasdaq.com/articles/abbv%3A-phase-3-study-confirms-upadacitinib-improved-clinical-endoscopic-outcomes-in-crohns | null | null | (RTTNews) - AbbVie (ABBV) said that the second phase 3 induction study confirmed Upadacitinib (RINVOQ) improved clinical and endoscopic outcomes in patients with moderate to severe Crohn's disease.
In U-EXCEL, the second of two Phase 3 induction studies, a significantly higher proportion of patients with moderate to se... | (RTTNews) - AbbVie (ABBV) said that the second phase 3 induction study confirmed Upadacitinib (RINVOQ) improved clinical and endoscopic outcomes in patients with moderate to severe Crohn's disease. Upadacitinib, a selective and reversible JAK inhibitor discovered and developed by AbbVie, is being studied as an oral the... | (RTTNews) - AbbVie (ABBV) said that the second phase 3 induction study confirmed Upadacitinib (RINVOQ) improved clinical and endoscopic outcomes in patients with moderate to severe Crohn's disease. Upadacitinib, a selective and reversible JAK inhibitor discovered and developed by AbbVie, is being studied as an oral the... | (RTTNews) - AbbVie (ABBV) said that the second phase 3 induction study confirmed Upadacitinib (RINVOQ) improved clinical and endoscopic outcomes in patients with moderate to severe Crohn's disease. Upadacitinib, a selective and reversible JAK inhibitor discovered and developed by AbbVie, is being studied as an oral the... | (RTTNews) - AbbVie (ABBV) said that the second phase 3 induction study confirmed Upadacitinib (RINVOQ) improved clinical and endoscopic outcomes in patients with moderate to severe Crohn's disease. Upadacitinib, a selective and reversible JAK inhibitor discovered and developed by AbbVie, is being studied as an oral the... |
23,584 | 2022-02-23 00:00:00 UTC | 7 High-Yield Blue-Chip Stocks Suitable for Any Retiree | ABBV | https://www.nasdaq.com/articles/7-high-yield-blue-chip-stocks-suitable-for-any-retiree | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Investors seeking safety, value, and income are running out of choices. The mounting volatility in the stock market is hurting the stock’s safety. Stock markets are assessing January’s 7.5% consumer price index. This is raising volatility and creating the i... | Investors who took a risk and bought ABBV stock years ago when it dipped in the $70 range are being rewarded today. 7 Sin Stocks to Buy if the Economy Slows Down Here are seven picks for blue-chip stocks that will give any conservative investor a healthy level of diversification: AbbVie (NYSE:ABBV) BP p.l.c. Blue-Chip ... | Blue-Chip Stocks: AbbVie (ABBV) Source: Piotr Swat / Shutterstock.com In the fourth quarter (Q4) for 2021, AbbVie posted diluted earnings per share (EPS) of $2.26, up by 100% year-over-year (YOY). 7 Sin Stocks to Buy if the Economy Slows Down Here are seven picks for blue-chip stocks that will give any conservative inv... | 7 Sin Stocks to Buy if the Economy Slows Down Here are seven picks for blue-chip stocks that will give any conservative investor a healthy level of diversification: AbbVie (NYSE:ABBV) BP p.l.c. Blue-Chip Stocks: AbbVie (ABBV) Source: Piotr Swat / Shutterstock.com In the fourth quarter (Q4) for 2021, AbbVie posted dilut... | 7 Sin Stocks to Buy if the Economy Slows Down Here are seven picks for blue-chip stocks that will give any conservative investor a healthy level of diversification: AbbVie (NYSE:ABBV) BP p.l.c. Blue-Chip Stocks: AbbVie (ABBV) Source: Piotr Swat / Shutterstock.com In the fourth quarter (Q4) for 2021, AbbVie posted dilut... |
23,585 | 2022-02-23 00:00:00 UTC | MGV, BRK.B, JNJ, ABBV: Large Inflows Detected at ETF | ABBV | https://www.nasdaq.com/articles/mgv-brk.b-jnj-abbv%3A-large-inflows-detected-at-etf | null | null | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Vanguard Mega Cap Value ETF (Symbol: MGV) where we have detected an approximate $165.6 million dollar inflow -- that's a 3.4% increase week over week in outstanding units (from 46,760,539 to... | Among the largest underlying components of MGV, in trading today Berkshire Hathaway Inc New (Symbol: BRK.B) is off about 0.4%, Johnson & Johnson (Symbol: JNJ) is off about 0.1%, and AbbVie Inc (Symbol: ABBV) is higher by about 0.8%. For a complete list of holdings, visit the MGV Holdings page » The chart below shows th... | Among the largest underlying components of MGV, in trading today Berkshire Hathaway Inc New (Symbol: BRK.B) is off about 0.4%, Johnson & Johnson (Symbol: JNJ) is off about 0.1%, and AbbVie Inc (Symbol: ABBV) is higher by about 0.8%. For a complete list of holdings, visit the MGV Holdings page » The chart below shows th... | Among the largest underlying components of MGV, in trading today Berkshire Hathaway Inc New (Symbol: BRK.B) is off about 0.4%, Johnson & Johnson (Symbol: JNJ) is off about 0.1%, and AbbVie Inc (Symbol: ABBV) is higher by about 0.8%. Looking today at week-over-week shares outstanding changes among the universe of ETFs c... | Among the largest underlying components of MGV, in trading today Berkshire Hathaway Inc New (Symbol: BRK.B) is off about 0.4%, Johnson & Johnson (Symbol: JNJ) is off about 0.1%, and AbbVie Inc (Symbol: ABBV) is higher by about 0.8%. Looking today at week-over-week shares outstanding changes among the universe of ETFs c... |
23,586 | 2022-02-22 00:00:00 UTC | Want to Get Richer? 5 Best Stocks to Buy Now and Hold Forever | ABBV | https://www.nasdaq.com/articles/want-to-get-richer-5-best-stocks-to-buy-now-and-hold-forever | null | null | Creating wealth in the stock market can be as simple as owning pieces of the world's most powerful corporations and letting them compound for decades. But you can't pick just any stock; most won't cut it over the long-term.
Sometimes if it's broken, don't fix it. Some companies have been compounding for decades, and ar... | The company retooled itself over the past decade after spinning off most of its pharmaceutical business as AbbVie in 2013. Creating wealth in the stock market can be as simple as owning pieces of the world's most powerful corporations and letting them compound for decades. Whether you're a homeowner remodeling or slapp... | The company retooled itself over the past decade after spinning off most of its pharmaceutical business as AbbVie in 2013. Abbott Laboratories (NYSE: ABT) is a healthcare conglomerate that sells consumer products, medical devices, and generic pharmaceutical drugs. The Motley Fool owns and recommends Amazon, Apple, Berk... | The company retooled itself over the past decade after spinning off most of its pharmaceutical business as AbbVie in 2013. Berkshire Hathaway Investing in holding company Berkshire Hathaway (NYSE: BRK.B) means trusting your money with investing legends like Charlie Munger and Warren Buffett, who still run the ship ther... | The company retooled itself over the past decade after spinning off most of its pharmaceutical business as AbbVie in 2013. * They just revealed what they believe are the ten best stocks for investors to buy right now... and Berkshire Hathaway (A shares) wasn't one of them! That's right -- they think these 10 stocks are... |
23,587 | 2022-02-22 00:00:00 UTC | Viatris (VTRS) to Report Q4 Earnings: What's in the Cards? | ABBV | https://www.nasdaq.com/articles/viatris-vtrs-to-report-q4-earnings%3A-whats-in-the-cards | null | null | Viatris VTRS, a global healthcare company, is scheduled to report fourth-quarter 2021 results on Feb 28.
The company was formed in 2020 through the combination of Mylan and Upjohn. It beat earnings estimates in each of the trailing four quarters, the average surprise being 14.3%. In the last reported quarter, the compa... | Other Updates Earlier in the month, Viatris announced that its subsidiary, Mylan Pharmaceuticals Inc., has received approval from the FDA for its abbreviated new drug application (ANDA) for cyclosporine ophthalmic emulsion 0.05%, the first generic version of Restasis, developed by Allergan, an AbbVie ABBV company. AbbV... | AbbVie Inc. (ABBV): Free Stock Analysis Report Other Updates Earlier in the month, Viatris announced that its subsidiary, Mylan Pharmaceuticals Inc., has received approval from the FDA for its abbreviated new drug application (ANDA) for cyclosporine ophthalmic emulsion 0.05%, the first generic version of Restasis, deve... | Other Updates Earlier in the month, Viatris announced that its subsidiary, Mylan Pharmaceuticals Inc., has received approval from the FDA for its abbreviated new drug application (ANDA) for cyclosporine ophthalmic emulsion 0.05%, the first generic version of Restasis, developed by Allergan, an AbbVie ABBV company. AbbV... | Other Updates Earlier in the month, Viatris announced that its subsidiary, Mylan Pharmaceuticals Inc., has received approval from the FDA for its abbreviated new drug application (ANDA) for cyclosporine ophthalmic emulsion 0.05%, the first generic version of Restasis, developed by Allergan, an AbbVie ABBV company. AbbV... |
23,588 | 2022-02-21 00:00:00 UTC | AbbVie Is a Top Pick in an Uncertain Market | ABBV | https://www.nasdaq.com/articles/abbvie-is-a-top-pick-in-an-uncertain-market | null | null | A host of macroeconomic issues have rattled the stock market and the economy so far in 2022. Major U.S. indices are down for the year. Some, like the Nasdaq, are down more than 10% year to date amid volatile trading.
AbbVie (NYSE: ABBV), on the other hand, has been on a tear, gaining over 20% in the last six months, an... | Investors will also look for a safe haven in areas like consumer staples, utilities, defense stocks, and pharmaceutical companies like AbbVie. Solidifying the future AbbVie may be best-known for Humira, a medication that treats moderate to severe Crohn's disease and has been highly successful. While the overall market ... | As the chart below shows, AbbVie's total quarterly revenue has grown from $8.6 billion in the first quarter of 2020 to nearly $14.9 billion in the fourth quarter of 2021: Data source: AbbVie. A solid and growing dividend AbbVie's stock dividend is also a significant attraction, currently standing at $1.41 quarterly or ... | As the chart below shows, AbbVie's total quarterly revenue has grown from $8.6 billion in the first quarter of 2020 to nearly $14.9 billion in the fourth quarter of 2021: Data source: AbbVie. A solid and growing dividend AbbVie's stock dividend is also a significant attraction, currently standing at $1.41 quarterly or ... | Since AbbVie's inception in 2013, the dividend has increased each year. AbbVie's stock has seen significant gains recently, and the stock will likely continue to reward long-term investors into the future. AbbVie (NYSE: ABBV), on the other hand, has been on a tear, gaining over 20% in the last six months, and over 6% y... |
23,589 | 2022-02-21 00:00:00 UTC | Here's How Much You Can Retire With by Investing Just $2,827 Every Year | ABBV | https://www.nasdaq.com/articles/heres-how-much-you-can-retire-with-by-investing-just-%242827-every-year | null | null | The average refund for the 2020 tax year was $2,827. While many people treat those refunds as windfalls to be spent on splurges such as vacations or large purchases, paying down debt -- particularly high-interest rate debt -- is a better option. But if you don't have any high-interest rate debt (and you do have suffici... | Top industry performers such as UnitedHealth Group, Johnson & Johnson, and AbbVie, along with Pfizer, each compose more than 5% of the fund's weight. But if you don't have any high-interest rate debt (and you do have sufficient money set aside in an emergency fund), the smartest option for putting your tax refund to go... | Top industry performers such as UnitedHealth Group, Johnson & Johnson, and AbbVie, along with Pfizer, each compose more than 5% of the fund's weight. Over the past 10 years, the healthcare stock has generated total returns (including dividends) of approximately 260%, which equates to a compound annual growth rate of 13... | Top industry performers such as UnitedHealth Group, Johnson & Johnson, and AbbVie, along with Pfizer, each compose more than 5% of the fund's weight. The power of compound growth Investing $2,827 each year into stock would mean that over the course of 20 years, you'd contribute more than $56,000. Over the past 10 years... | Top industry performers such as UnitedHealth Group, Johnson & Johnson, and AbbVie, along with Pfizer, each compose more than 5% of the fund's weight. The power of compound growth Investing $2,827 each year into stock would mean that over the course of 20 years, you'd contribute more than $56,000. Over the past 10 years... |
23,590 | 2022-02-20 00:00:00 UTC | Investing $20,000 in These 5 Stocks Could Give You $6,000 in Annual Income | ABBV | https://www.nasdaq.com/articles/investing-%2420000-in-these-5-stocks-could-give-you-%246000-in-annual-income | null | null | Make your money work for you. That's good advice for any investor. But it's great advice for income-seeking investors.
Dividend stocks provide an excellent way to put your money to work -- especially with certain stocks. Investing $20,000 in each of these five stocks could give you roughly $6,000 in annual income.
Imag... | Don't worry about the impending loss of patent exclusivity in the U.S. for AbbVie's top-selling drug Humira next year. AbbVie Juicy dividends and reliability. AbbVie (NYSE: ABBV) offers them both. | AbbVie Juicy dividends and reliability. AbbVie (NYSE: ABBV) offers them both. AbbVie is also a Dividend Aristocrat with a long streak of annual dividend increases. | AbbVie is also a Dividend Aristocrat with a long streak of annual dividend increases. See the 10 stocks *Stock Advisor returns as of January 20, 2022 Keith Speights owns AbbVie, Devon Energy, and Enterprise Products Partners. AbbVie Juicy dividends and reliability. | AbbVie is also a Dividend Aristocrat with a long streak of annual dividend increases. * They just revealed what they believe are the ten best stocks for investors to buy right now... and AbbVie wasn't one of them! AbbVie Juicy dividends and reliability. |
23,591 | 2022-02-19 00:00:00 UTC | This Number Is a Big Green Flag for AbbVie Stock | ABBV | https://www.nasdaq.com/articles/this-number-is-a-big-green-flag-for-abbvie-stock | null | null | Investors might be numb to the common reminder that "past performance is no guarantee of future returns," but that doesn't stop companies like AbbVie (NYSE: ABBV) from working hard to replicate their prior successes. With the end of patent exclusivity looming for its rock star drug, Humira, the pharma juggernaut is scr... | Investors might be numb to the common reminder that "past performance is no guarantee of future returns," but that doesn't stop companies like AbbVie (NYSE: ABBV) from working hard to replicate their prior successes. Finding new sources of revenue to replace the sales it's going to lose is of paramount importance for A... | Despite Humira's steep international revenue drop, growth from the combination of Skyrizi and Rinvoq led the international segment of AbbVie's immunology portfolio to gain 0.5% in Q4. Investors might be numb to the common reminder that "past performance is no guarantee of future returns," but that doesn't stop companie... | Finding new sources of revenue to replace the sales it's going to lose is of paramount importance for Abbvie, which is why the company has been developing a pair of drugs, Rinvoq and Skyrizi, which between them can treat all of the same conditions as Humira. Despite Humira's steep international revenue drop, growth fro... | Finding new sources of revenue to replace the sales it's going to lose is of paramount importance for Abbvie, which is why the company has been developing a pair of drugs, Rinvoq and Skyrizi, which between them can treat all of the same conditions as Humira. Despite Humira's steep international revenue drop, growth fro... |
23,592 | 2022-02-18 00:00:00 UTC | 7 Value Stocks to Buy in This Pricey Market | ABBV | https://www.nasdaq.com/articles/7-value-stocks-to-buy-in-this-pricey-market | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Value stocks are always in fashion. But after nearly 18 months where investors could find growth in usual and unusual places, value stocks got crowded out. This time, they said, was different.
It wasn’t and it isn’t. If the recent market selloff has taught ... | Like most value stocks, these are mature companies many of which pay dividends: Target (NYSE:TGT) Dick’s Sporting Goods (NYSE:DKS) AbbVie (NYSE:ABBV) Ford (NYSE:F) Rent-A-Center (NASDAQ:RCII) Winnebago (NYSE:WGO) Darden Restaurants (NYSE:DRI) Value Stocks: Target (TGT) Source: jejim / Shutterstock.com The economy recei... | Like most value stocks, these are mature companies many of which pay dividends: Target (NYSE:TGT) Dick’s Sporting Goods (NYSE:DKS) AbbVie (NYSE:ABBV) Ford (NYSE:F) Rent-A-Center (NASDAQ:RCII) Winnebago (NYSE:WGO) Darden Restaurants (NYSE:DRI) Value Stocks: Target (TGT) Source: jejim / Shutterstock.com The economy recei... | Like most value stocks, these are mature companies many of which pay dividends: Target (NYSE:TGT) Dick’s Sporting Goods (NYSE:DKS) AbbVie (NYSE:ABBV) Ford (NYSE:F) Rent-A-Center (NASDAQ:RCII) Winnebago (NYSE:WGO) Darden Restaurants (NYSE:DRI) Value Stocks: Target (TGT) Source: jejim / Shutterstock.com The economy recei... | However, after delivering a mixed earnings report (the company beat on earnings but missed on revenue), JPMorgan boosted its price target for AbbVie to $180, which would be a gain of nearly 25%. Even with less growth, many investors buy AbbVie for the reliable dividend. Like most value stocks, these are mature companie... |
23,593 | 2022-02-18 00:00:00 UTC | Ironwood (IRWD) Q4 Earnings Miss, Linzess Volume Grows | ABBV | https://www.nasdaq.com/articles/ironwood-irwd-q4-earnings-miss-linzess-volume-grows | null | null | Ironwood Pharmaceuticals, Inc. IRWD reported fourth-quarter 2021 adjusted earnings of 27 cents per share, missing the Zacks Consensus Estimate of 31 cents. The company had reported adjusted earnings of 36 cents per share in the year-ago quarter.
Total revenues of $117.1 million beat the Zacks Consensus Estimate of $109... | Image Source: Zacks Investment Research Quarter in Detail As reported by partner AbbVie ABBV, Ironwood’s sole marketed product — Linzess — generated net sales of almost $278.6 million in the United States, flat year over year. Ironwood and AbbVie equally share Linzess’ brand collaboration profits or losses. AbbVie Inc.... | Image Source: Zacks Investment Research Quarter in Detail As reported by partner AbbVie ABBV, Ironwood’s sole marketed product — Linzess — generated net sales of almost $278.6 million in the United States, flat year over year. Ironwood and AbbVie equally share Linzess’ brand collaboration profits or losses. AbbVie Inc.... | Image Source: Zacks Investment Research Quarter in Detail As reported by partner AbbVie ABBV, Ironwood’s sole marketed product — Linzess — generated net sales of almost $278.6 million in the United States, flat year over year. Ironwood and AbbVie equally share Linzess’ brand collaboration profits or losses. AbbVie Inc.... | Image Source: Zacks Investment Research Quarter in Detail As reported by partner AbbVie ABBV, Ironwood’s sole marketed product — Linzess — generated net sales of almost $278.6 million in the United States, flat year over year. Ironwood and AbbVie equally share Linzess’ brand collaboration profits or losses. AbbVie Inc.... |
23,594 | 2022-02-18 00:00:00 UTC | Zacks Value Trader Highlights: Mastercard, Visa, Chevron and AbbVie | ABBV | https://www.nasdaq.com/articles/zacks-value-trader-highlights%3A-mastercard-visa-chevron-and-abbvie | null | null | For Immediate Release
Chicago, IL – February 18, 2022 – Zacks Value Trader is a podcast hosted weekly by Zacks Stock Strategist Tracey Ryniec. Every week, Tracey will be joined by guests to discuss the hottest investing topics in stocks, bonds and ETFs and how it impacts your life. To listen to the podcast, click here:... | (16:30) - Big Takeaways From The 13F Filing: ATVI, CVX, MA, V, ABBV, RH Podcast@Zacks.com Every week, Tracey Ryniec, the editor of Zacks Value Investor portfolio, shares some of her top value investing tips and stock picks. AbbVie ABBV AbbVie was added to the Berkshire portfolio in the third quarter of 2020. AbbVie see... | (16:30) - Big Takeaways From The 13F Filing: ATVI, CVX, MA, V, ABBV, RH Podcast@Zacks.com Every week, Tracey Ryniec, the editor of Zacks Value Investor portfolio, shares some of her top value investing tips and stock picks. AbbVie Inc. (ABBV): Free Stock Analysis Report AbbVie ABBV AbbVie was added to the Berkshire por... | (16:30) - Big Takeaways From The 13F Filing: ATVI, CVX, MA, V, ABBV, RH Podcast@Zacks.com Every week, Tracey Ryniec, the editor of Zacks Value Investor portfolio, shares some of her top value investing tips and stock picks. AbbVie ABBV AbbVie was added to the Berkshire portfolio in the third quarter of 2020. AbbVie see... | (16:30) - Big Takeaways From The 13F Filing: ATVI, CVX, MA, V, ABBV, RH Podcast@Zacks.com Every week, Tracey Ryniec, the editor of Zacks Value Investor portfolio, shares some of her top value investing tips and stock picks. AbbVie ABBV AbbVie was added to the Berkshire portfolio in the third quarter of 2020. AbbVie see... |
23,595 | 2022-02-18 00:00:00 UTC | AbbVie Snags FDA Approval for Another Indication. Will It Become Another Blockbuster? | ABBV | https://www.nasdaq.com/articles/abbvie-snags-fda-approval-for-another-indication.-will-it-become-another-blockbuster | null | null | AbbVie (NYSE: ABBV) has taken an important step toward replacing the revenue decline that will result from Humira's patent protection expiration in the U.S. next year.
That step is approval from the U.S. Food and Drug Administration (FDA) to use AbbVie's Skyrizi to treat patients with active psoriatic arthritis, a dise... | That step is approval from the U.S. Food and Drug Administration (FDA) to use AbbVie's Skyrizi to treat patients with active psoriatic arthritis, a disease that impacts around 1.5 million Americans. AbbVie conducted two phase 3 clinical trials with patients who weren't able to achieve meaningful improvement or were una... | That step is approval from the U.S. Food and Drug Administration (FDA) to use AbbVie's Skyrizi to treat patients with active psoriatic arthritis, a disease that impacts around 1.5 million Americans. Let's dive into the phase 3 clinical trial results for Skyrizi and the U.S. psoriatic arthritis market to get a feel for ... | That step is approval from the U.S. Food and Drug Administration (FDA) to use AbbVie's Skyrizi to treat patients with active psoriatic arthritis, a disease that impacts around 1.5 million Americans. AbbVie is a great income stock Aside from Skyrizi, AbbVie has dozens of drug indications that are in different stages of ... | Let's dive into the phase 3 clinical trial results for Skyrizi and the U.S. psoriatic arthritis market to get a feel for how valuable this approval could be for AbbVie. AbbVie (NYSE: ABBV) has taken an important step toward replacing the revenue decline that will result from Humira's patent protection expiration in the... |
23,596 | 2022-02-17 00:00:00 UTC | Daily Dividend Report: HUM,CSCO,WCN,SWK,ABBV | ABBV | https://www.nasdaq.com/articles/daily-dividend-report%3A-humcscowcnswkabbv | null | null | Humana announced today that its Board of Directors has declared a cash dividend to stockholders of $0.7875 per share payable on April 29, 2022 to stockholders of record as of the close of business on March 31, 2022. The dividend of $0.7875 per share reflects an increase of 12.5 percent from the previous per share divid... | The board of directors of AbbVie today declared a quarterly cash dividend of $1.41 per share. Since the company's inception in 2013, AbbVie has increased its dividend by more than 250 percent. AbbVie is a member of the S&P Dividend Aristocrats Index, which tracks companies that have annually increased their dividend fo... | The board of directors of AbbVie today declared a quarterly cash dividend of $1.41 per share. Since the company's inception in 2013, AbbVie has increased its dividend by more than 250 percent. AbbVie is a member of the S&P Dividend Aristocrats Index, which tracks companies that have annually increased their dividend fo... | The board of directors of AbbVie today declared a quarterly cash dividend of $1.41 per share. Since the company's inception in 2013, AbbVie has increased its dividend by more than 250 percent. AbbVie is a member of the S&P Dividend Aristocrats Index, which tracks companies that have annually increased their dividend fo... | The board of directors of AbbVie today declared a quarterly cash dividend of $1.41 per share. Since the company's inception in 2013, AbbVie has increased its dividend by more than 250 percent. AbbVie is a member of the S&P Dividend Aristocrats Index, which tracks companies that have annually increased their dividend fo... |
23,597 | 2022-02-16 00:00:00 UTC | Abbvie Inc Shares Climb 0.3% Past Previous 52-Week High - Market Mover | ABBV | https://www.nasdaq.com/articles/abbvie-inc-shares-climb-0.3-past-previous-52-week-high-market-mover | null | null | Abbvie Inc (ABBV) shares closed 0.3% higher than its previous 52 week high, giving the company a market cap of $255B. The stock is currently up 8.0% year-to-date, up 45.1% over the past 12 months, and up 195.6% over the past five years. This week, the Dow Jones Industrial Average fell 1.2%, and the S&P 500 fell 1.1%.
T... | Abbvie Inc (ABBV) shares closed 0.3% higher than its previous 52 week high, giving the company a market cap of $255B. Beta, a measure of the stock’s volatility relative to the overall market stands at 0.4. Market Comparative Performance The company's share price is the same as the S&P 500 Index , beats it on a 1-year b... | Abbvie Inc (ABBV) shares closed 0.3% higher than its previous 52 week high, giving the company a market cap of $255B. This week, the Dow Jones Industrial Average fell 1.2%, and the S&P 500 fell 1.1%. Market Comparative Performance The company's share price is the same as the S&P 500 Index , beats it on a 1-year basis, ... | Abbvie Inc (ABBV) shares closed 0.3% higher than its previous 52 week high, giving the company a market cap of $255B. Market Comparative Performance The company's share price is the same as the S&P 500 Index , beats it on a 1-year basis, and beats it on a 5-year basis The company's share price is the same as the Dow Jo... | Abbvie Inc (ABBV) shares closed 0.3% higher than its previous 52 week high, giving the company a market cap of $255B. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Ind... |
23,598 | 2022-02-16 00:00:00 UTC | 2 Warren Buffett Stocks to Buy and Hold Forever | ABBV | https://www.nasdaq.com/articles/2-warren-buffett-stocks-to-buy-and-hold-forever | null | null | Warren Buffett, CEO of multinational conglomerate Berkshire Hathaway, is widely regarded as one of the greatest investors of our time. That means we can all learn a lot from his buy-and-hold approach to investing and perhaps even get some much-needed inspiration from his stock picks.
Buffett oversees his company's inve... | Buffett oversees his company's investment portfolio, and two stocks in there that are most definitely worth buying and holding onto today are drugmaker AbbVie (NYSE: ABBV) and tech giant Apple (NASDAQ: AAPL). AbbVie's portfolio includes immunology drugs Humira, Skyrizi, and Rinvoq; cancer medicines Imbruvica and Vencle... | Buffett oversees his company's investment portfolio, and two stocks in there that are most definitely worth buying and holding onto today are drugmaker AbbVie (NYSE: ABBV) and tech giant Apple (NASDAQ: AAPL). ABBV Total Return Level data by YCharts 1. AbbVie Pharmaceutical companies have the advantage of offering produ... | Buffett oversees his company's investment portfolio, and two stocks in there that are most definitely worth buying and holding onto today are drugmaker AbbVie (NYSE: ABBV) and tech giant Apple (NASDAQ: AAPL). ABBV Total Return Level data by YCharts 1. AbbVie Pharmaceutical companies have the advantage of offering produ... | Buffett oversees his company's investment portfolio, and two stocks in there that are most definitely worth buying and holding onto today are drugmaker AbbVie (NYSE: ABBV) and tech giant Apple (NASDAQ: AAPL). ABBV Total Return Level data by YCharts 1. AbbVie Pharmaceutical companies have the advantage of offering produ... |
23,599 | 2022-02-16 00:00:00 UTC | Why Abbvie Might Be Poised for a Return to Profitability | ABBV | https://www.nasdaq.com/articles/why-abbvie-might-be-poised-for-a-return-to-profitability | null | null | In this clip from "The Pharma & Biotech Show" on Motley Fool Live, recorded on Feb. 2, Motley Fool contributors Keith Speights and Brian Orelli assess the pharma giant's projection that it'll return to growth quickly in the second half of the decade.
{% sfr %}
Keith Speights: Here's the statement that really jumped ou... | I'm going to read this, "AbbVie (NYSE: ABBV) confirmed prior revenue guidance of greater than $15 billion in combined Skyrizi and Rinvoq risk-adjusted sales in 2025. AbbVie expects each asset to deliver risk-adjusted sales of greater than $7.5 billion in 2025." AbbVie is sticking with its projection even though the FDA... | I'm going to read this, "AbbVie (NYSE: ABBV) confirmed prior revenue guidance of greater than $15 billion in combined Skyrizi and Rinvoq risk-adjusted sales in 2025. AbbVie expects each asset to deliver risk-adjusted sales of greater than $7.5 billion in 2025." AbbVie is sticking with its projection even though the FDA... | If AbbVie's correct and it's two newer autoimmune disease drugs break in over $15 billion by 2025, and Humira goes on a steady decline over the next few years in the U.S. market, I think AbbVie could be right that they return to growth pretty quickly in the second half of this decade. I'm going to read this, "AbbVie (N... | If AbbVie's correct and it's two newer autoimmune disease drugs break in over $15 billion by 2025, and Humira goes on a steady decline over the next few years in the U.S. market, I think AbbVie could be right that they return to growth pretty quickly in the second half of this decade. I'm going to read this, "AbbVie (N... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.